Obatoclax Mesylate (GX15-070)

Name: Obatoclax Mesylate (GX15-070)
Brand: Selleck Chemicals
SKU: S1057
Rating: 5 (99 reviews)

For research use only.

Catalog No.S1057

99 publications

Obatoclax Mesylate (GX15-070) Chemical Structure

CAS No. 803712-79-0

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Selleck's Obatoclax Mesylate (GX15-070) has been cited by 99 publications

Cancer Cell, 2019, 36(1):68-83

PubMed: 31257073 ( click the link to review the publication )

Nature, 2017, 551(7679):247-250

PubMed: 29088702 ( click the link to review the publication )

Cell, 2010, 20;142(4):590-600.

PubMed: 20723759 ( click the link to review the publication )

Biomaterials, 2020, 232:119709

PubMed: 31896513 ( click the link to review the publication )

Int J Mol Sci, 2020, 5;21(5) pii: E1773

PubMed: 32150830 ( click the link to review the publication )

Invest New Drugs, 2020, 4

PubMed: 32367199 ( click the link to review the publication )

NPJ Breast Cancer, 2020, 6:30

PubMed: 32715085 ( click the link to review the publication )

Cell Chem Biol, 2019, 10.1016/j.chembiol.2019.04.011

PubMed: 31155509 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(6)

PubMed: 30875757 ( click the link to review the publication )

Front Microbiol, 2019, 10:2236

PubMed: 31636613 ( click the link to review the publication )

Prostate, 2019, 79(11):1347-1359

PubMed: 31228231 ( click the link to review the publication )

Cancers (Basel), 2018, 10(12)

PubMed: 30563080 ( click the link to review the publication )

Cell Death Discov, 2018, 4:107

PubMed: 30479840 ( click the link to review the publication )

Cell Death Dis, 2018, 92(10)

PubMed: 23640461 ( click the link to review the publication )

Antioxidants (Basel), 2018, 10.3390/antiox7110150

PubMed: 30373097 ( click the link to review the publication )

BMC Cancer, 2018, 18(1):965

PubMed: 30305055 ( click the link to review the publication )

J Clin Invest, 2017, 127(1):153-168

PubMed: 27893461 ( click the link to review the publication )

Cancer Res, 2017, 77(13):3513-3526

PubMed: 28522750 ( click the link to review the publication )

Cancer Res, 2017, 10.1158/0008-5472.CAN-16-3424

PubMed: ( click the link to review the publication )

Genome Med, 2017, 9(1):40

PubMed: 28446242 ( click the link to review the publication )

J Exp Clin Cancer Res, 2017, 36(1):52

PubMed: 28403890 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

FEBS J, 2017, 284(2):222-236

PubMed: 27860276 ( click the link to review the publication )

Antimicrob Agents Chemother, 2017, 61(3)

PubMed: 27993855 ( click the link to review the publication )
Electrophoresis, 2017, 10.1002/elps.201600447

PubMed: 28608427 ( click the link to review the publication )

J Exp Med, 2017, 214(6):1691-1710

PubMed: 28450382 ( click the link to review the publication )

Oncotarget, 2017, 8(5):8670-8678

PubMed: 28055968 ( click the link to review the publication )

Viruses, 2017, 9(10)

PubMed: 28946654 ( click the link to review the publication )

Blood, 2016, 6;128(14):1834-1844

PubMed: 27465916 ( click the link to review the publication )

Nat Commun, 2016, 7:11190

PubMed: 27048913 ( click the link to review the publication )

Autophagy, 2016, 2;12(6):999-1014

PubMed: 27124102 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(21):5370-5382

PubMed: 27178741 ( click the link to review the publication )

ACS Appl Mater Interfaces, 2016, 8(21):13218-31

PubMed: 27160664 ( click the link to review the publication )

Antiviral Res, 2016, 126:69-80

PubMed: 26738783 ( click the link to review the publication )

Cancer Cell Int, 2016, 16:27

PubMed: 27042160 ( click the link to review the publication )

Int J Oncol, 2016, 49(3):953-60

PubMed: 27572939 ( click the link to review the publication )

Oncotarget, 2016, 7(3):3520-32

PubMed: 26657288 ( click the link to review the publication )

Tumour Biol, 2016, 37(8):10839-49

PubMed: 26880588 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(10):2357-2369

PubMed: 27512118 ( click the link to review the publication )

Oncotarget, 2016, 7(35):56253-56265

PubMed: 27494845 ( click the link to review the publication )

Oncotarget, 2016,

PubMed: 26910910 ( click the link to review the publication )

Oncotarget, 2016, 8(36):60060-60079

PubMed: 28947954 ( click the link to review the publication )

Oncotarget, 2016, 7(23):34453-71

PubMed: 27144341 ( click the link to review the publication )

Nat Chem Biol, 2015, 10.1038/nchembio.1986

PubMed: 26656090 ( click the link to review the publication )

Genes Dev, 2015, 29(20):2140-52

PubMed: 26494789 ( click the link to review the publication )

Int J Cancer, 2015, 137(12):2959-70

PubMed: 26096065 ( click the link to review the publication )

Cancer Lett, 2015, 10.1016/j.canlet.2015.05.008

PubMed: 25979228 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e2014

PubMed: 26658189 ( click the link to review the publication )
Mol Oncol, 2015, 9(2):409-21

PubMed: 25308513 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):409-21

PubMed: ( click the link to review the publication )

J Biol Chem, 2015, 290(34):20841-55

PubMed: 26124276 ( click the link to review the publication )

Cancer Cell Int, 2015, 15:97

PubMed: 26464561 ( click the link to review the publication )

Int J Oncol, 2015, 46(4):1844-8

PubMed: 25647738 ( click the link to review the publication )

BMC Cancer, 2015, 15:919

PubMed: 26585594 ( click the link to review the publication )

Open Biol, 2015, 5(3)

PubMed: 25761368 ( click the link to review the publication )

Mol Cells, 2015, 38(3):279-84

PubMed: 25666350 ( click the link to review the publication )

Oral Dis, 2015,

PubMed: 25482163 ( click the link to review the publication )

Cell Biochem Funct, 2015, 33(5):334-40

PubMed: 26178811 ( click the link to review the publication )

Anticancer Drugs, 2015, 26(3):331-42

PubMed: 25521557 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 26008975 ( click the link to review the publication )

Arch Pharm Chem Life Sci, 2015, 348: 1-11

PubMed: 25641608 ( click the link to review the publication )

J Pharm Pharmacol, 2015, 67(11):1575-84

PubMed: 26255619 ( click the link to review the publication )

Oncotarget, 2015, 6(40):42445-67

PubMed: 26636651 ( click the link to review the publication )

Oncotarget, 2015,

PubMed: 25749045 ( click the link to review the publication )

Cancer Lett, 2014, 348(1-2):20-8

PubMed: 24534203 ( click the link to review the publication )

Endocr Relat Cancer, 2014, 21(5):755-67

PubMed: 25012986 ( click the link to review the publication )

Oral Oncol, 2014, 50(2):120-7

PubMed: 24216166 ( click the link to review the publication )

Antimicrob Agents Chemother, 2014, 58(7):3689-96

PubMed: 24752266 ( click the link to review the publication )

Biochem Pharmacol, 2014, 92(1):55-61

PubMed: 25107702 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26481-91

PubMed: 25096574 ( click the link to review the publication )

Exp Cell Res, 2014, 322(1):217-25

PubMed: 24355809 ( click the link to review the publication )

Life Sci, 2014, 10.1016/j.lfs.2014.07.006

PubMed: 25066930 ( click the link to review the publication )
Oncol Rep, 2014, 32(6):2789-94

PubMed: 25333301 ( click the link to review the publication )

J Cell Biochem, 2014, 115(9):1624-35

PubMed: 24788582 ( click the link to review the publication )

PLoS One, 2014, 9(11):e111927

PubMed: 25409302 ( click the link to review the publication )

PLoS One, 2014, 9(10):e111146

PubMed: 25343454 ( click the link to review the publication )

PLoS One, 2014, 9(9):e106571

PubMed: 25192188 ( click the link to review the publication )

Genes Cancer, 2014, 5(11-12):445-59

PubMed: 25568669 ( click the link to review the publication )

Erasmus University Rotterdam, 2014, 978-94-6259-077-9

PubMed: http://repub.eur.nl/pub/50827/ ( click the link to review the publication )

Assay Drug Dev Technol, 2014, 12(9-10):514-26

PubMed: 25506801 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2013, 110(11):4321-6

PubMed: 23447565 ( click the link to review the publication )

Int J Cancer, 2013, 133(8):1813-24

PubMed: 23580240 ( click the link to review the publication )

Cell Death Dis, 2013,

PubMed: 23681223 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e742

PubMed: 23887633 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(4):448-59

PubMed: 23395885 ( click the link to review the publication )

J Immunol, 2013, 190(9):4621-6

PubMed: 23547112 ( click the link to review the publication )

Apoptosis, 2013, 18(10):1163-74

PubMed: 23887890 ( click the link to review the publication )

Am J Respir Cell Mol Biol, 2013, 49(4):609-18

PubMed: 23668615 ( click the link to review the publication )

Exp Cell Res, 2013, 319(10):1443-50

PubMed: 23416067 ( click the link to review the publication )

PLoS One, 2013, 8(2):e55982

PubMed: 23418490 ( click the link to review the publication )

Helsinki Metropolia University, 2013, Jens Desloovere

PubMed: ( click the link to review the publication )

Cancer Res, 2012, 72(12):3069-79

PubMed: 22525702 ( click the link to review the publication )

Oncogene, 2012, 32(37):4331-42

PubMed: 23085751 ( click the link to review the publication )

Cancer Lett, 2012, 339(2):288-97

PubMed: 23200668 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e351

PubMed: 22825469 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e299

PubMed: 22513873 ( click the link to review the publication )
Toxicol Sci, 2012, 128(1):79-91

PubMed: 22491427 ( click the link to review the publication )

Cancer Res, 2011, 71(13):4494-505

PubMed: 21555370 ( click the link to review the publication )

BMC Cancer, 2011, 11:24

PubMed: 21247487 ( click the link to review the publication )

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Biological Activity

Description

Obatoclax Mesylate (GX15-070) is an antagonist of Bcl-2 with K_i of 0.22 μM in a cell-free assay, can assist in overcoming MCL-1 mediated resistance to apoptosis. Phase 3.

Features

Potential 1st-in-class small molecule antagonist of Bcl-2 designed to inhibit all relevant Bcl-2 family members, including Mcl-1.

Targets

Bcl-2 ^[1]
(Cell-free assay)

0.22 μM(Ki)

In vitro

Obatoclax completely inhibits Bak recovery of Mcl-1 at 5 μM in SK-Mel5 cells and overcomes resistance to ABT-373-induced apoptosis conferred by Mcl-1 in KB/Bcl-2 cells. ^[1] Obatoclax is a BH3 mimetic which binds to a broad spectrum of Bcl-2 family members, including Bcl-2, Bcl-xL, and Mcl-1. Obatoclax uniquely displaces BH3 domains by activation of the pocket of Mcl-1 followed by a triggering of apoptosis mediated by oligomerization of Bak and release of cytochrome c. Obatoclax is sensitive to Bcl-xL in cell lines lacking it or showing low expression. It shows low cytotoxicity to Mcl-1, Bcl-2, and Bcl-xL in all the strongly-expressed cell lines. Obatoclax inhibits multiple myeloma (MM) cell lines (KMS12PE, KMS18, MY5, etc.) with IC50 values ranging from 52 to 1100 nM and the inhibition is umimpaired even in the presence of IL-6 or IGF-1, which are resistance to cytotoxic agents, at a concentration of 150 nM. Obatoclax enhances the antimyeloma activity induced by melphalan, dexamethasone, or bortezomib. ^[2] Obatoclax potentiates TRAIL (tumor necrosis factor-related apoptosis-inducing ligand)-mediated apoptosis by unsequestering Bak and Bim from Bcl-2/Bcl-xL or Mcl-1 proteins in PANC-1 and BxPC-3 cells. ^[3]

Cell Data

Cell Lines	Assay Type	Activity Description	PMID
KARPAS-45	NWPYSoVCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTBwMECwNFMyPyEQvF2=	M1f6cHNCVkeHUh?=
SK-MEL-30	NIfLVVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVP3emRGUUN3ME2wMlAxODN3NTFOwG0>	MXfTRW5ITVJ?
NALM-6	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWPJR\|UxRTBwMECwN\|U3KM7:TR?=	MXHTRW5ITVJ?
KYSE-450	MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVn6RlBOUUN3ME2wMlAxODR4OTFOwG0>	NWD0bno3W0GQR1XS
BHY	NHnkU41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2j1XWlEPTB;MD6wNFA3ODFizszN	Mn3OV2FPT0WU
GR-ST	M{HVcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NWXRU\|VQUUN3ME2wMlAxODZ2ODFOwG0>	NY\Z[IRrW0GQR1XS
786-0	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MljKTWM2OD1yLkCwNFc4PiEQvF2=	NYjUdGMzW0GQR1XS
C-33-A	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlizTWM2OD1yLkCwNFg1QCEQvF2=	M{PoUXNCVkeHUh?=
BHT-101	M4nKV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mo\QTWM2OD1yLkCwNVA3KM7:TR?=	Mor5V2FPT0WU
EB2	NHfWe2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NU\rS2tqUUN3ME2wMlAxOTF6IN88US=>	M{X1RnNCVkeHUh?=
G-361	M4HB[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2n4SWlEPTB;MD6wNFEzPCEQvF2=	MoPkV2FPT0WU
KE-37	MmnKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYHJR\|UxRTBwMECxNlgh\|ryP	NXfhNnVmW0GQR1XS
MHH-PREB-1	NGi3PW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2jmN2lEPTB;MD6wNFE1KM7:TR?=	NFPNOlZUSU6JRWK=
MCF7	MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEfTZ\|VKSzVyPUCuNFAyPTlizszN	M2TSe3NCVkeHUh?=
LOUCY	MlL1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYTJR\|UxRTBwMECxO\|Uh\|ryP	M2nJdXNCVkeHUh?=
EW-7	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVPJR\|UxRTBwMECxO\|Uh\|ryP	M2\VTnNCVkeHUh?=
KYSE-510	NEXObYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX;OWmhJUUN3ME2wMlAxOjN\|IN88US=>	M3HUcnNCVkeHUh?=
SK-MEL-3	NYLPPJdST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWXYNFB{UUN3ME2wMlAxOjZ2IN88US=>	NXXiNplnW0GQR1XS
HAL-01	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXrJR\|UxRTBwMECyPVch\|ryP	NWradld5W0GQR1XS
HCC2998	NYXoXJBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mo\ZTWM2OD1yLkCwN\|M2KM7:TR?=	MUnTRW5ITVJ?
A375	NUDEVY9CT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HNNGlEPTB;MD6wNFM2KM7:TR?=	M12zcnNCVkeHUh?=
MZ7-mel	NXTneGROT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTBwMECzPVkh\|ryP	MWTTRW5ITVJ?
SH-4	NVvRZY8{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVTFS5l6UUN3ME2wMlAxPDF5IN88US=>	MV3TRW5ITVJ?
HT-144	NIHWVlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4[0S2lEPTB;MD6wNFQ{KM7:TR?=	M1rTWnNCVkeHUh?=
KYSE-140	NX24Wnh[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVnJR\|UxRTBwMEC0N\|Uh\|ryP	NEXuXJpUSU6JRWK=
PSN1	M3TucGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFeyVYlKSzVyPUCuNFA1PjdizszN	MVvTRW5ITVJ?
COLO-679	NGnEOlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NIP6c\|hKSzVyPUCuNFA1QThizszN	MkPJV2FPT0WU
SW620	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYTJR\|UxRTBwMEC1NVEh\|ryP	Mn3pV2FPT0WU
HGC-27	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnuR5BmUUN3ME2wMlAxPTJ2IN88US=>	MYjTRW5ITVJ?
IGROV-1	NV\PPFFWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTz[pFRUUN3ME2wMlAxPiEQvF2=	M1fRR3NCVkeHUh?=
IGR-1	NIXQW3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX2xbnkzUUN3ME2wMlAxPjBzIN88US=>	MUjTRW5ITVJ?
EW-1	MoOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVr3VnZbUUN3ME2wMlAxPjVzIN88US=>	MWrTRW5ITVJ?
769-P	M{PsbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlG5TWM2OD1yLkCwOlc5KM7:TR?=	MWHTRW5ITVJ?
HN	NWfiTVdqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PZOmlEPTB;MD6wNFY4QSEQvF2=	NF74fVFUSU6JRWK=
SIG-M5	M1TFSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3PhPWlEPTB;MD6wNFcyKM7:TR?=	NIfP[pBUSU6JRWK=
IST-MEL1	NYfIdoR6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUS2SZd[UUN3ME2wMlAxQDF6IN88US=>	MlixV2FPT0WU
ST486	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXzsb3IzUUN3ME2wMlAxQDJ3IN88US=>	NWnuTmZzW0GQR1XS
ES7	NH;yT4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTBwMEC4OFYh\|ryP	NFHwO2hUSU6JRWK=
GAK	NEXEPFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTBwMEC4OFgh\|ryP	Mnr5V2FPT0WU
BB30-HNC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXWbGlKUUN3ME2wMlAxQDV6IN88US=>	NIT5eHlUSU6JRWK=
IPC-298	NGPG[m5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTBwMEC5Nlch\|ryP	MYTTRW5ITVJ?
NKM-1	Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Moj0TWM2OD1yLkCwPVczKM7:TR?=	MlnHV2FPT0WU
RKO	NHS3eJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV7JR\|UxRTBwMEGwOFQh\|ryP	NV3RR3oxW0GQR1XS
ACN	NVro[Xd3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTBwMEGxN\|Eh\|ryP	Mn\yV2FPT0WU
SW1417	NIHHV41Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwMEGyNlUh\|ryP	MYrTRW5ITVJ?
SR	NVvnNYsyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmnoTWM2OD1yLkCxNlM2KM7:TR?=	M{jCPHNCVkeHUh?=
SNG-M	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX7JR\|UxRTBwMEGzNVch\|ryP	NYfWTm5nW0GQR1XS
CAL-12T	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHnNcI1KSzVyPUCuNFE{PDZizszN	MnLCV2FPT0WU
HSC-3	MnvmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwMEGzOVUh\|ryP	MWrTRW5ITVJ?
DOHH-2	NFTOemVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEToPWNKSzVyPUCuNFE1OTJizszN	NH\pTWpUSU6JRWK=
NB69	NI[5[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoHwTWM2OD1yLkCxOVY2KM7:TR?=	NHTicJRUSU6JRWK=
LC-2-ad	M3z5OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXezb3hyUUN3ME2wMlAyPThzIN88US=>	NXTnfIhlW0GQR1XS
RVH-421	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXfJR\|UxRTBwMEG2O\|Qh\|ryP	MUPTRW5ITVJ?
TGW	M3;ONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTBwMEG3N\|kh\|ryP	M{ewOHNCVkeHUh?=
HCC1569	NWfCfXRoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mn\hTWM2OD1yLkCxO\|k4KM7:TR?=	NYTvcZg1W0GQR1XS
CAL-85-1	NYXQTHU6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlSwTWM2OD1yLkCxPFMzKM7:TR?=	MV;TRW5ITVJ?
RPMI-8402	MkjyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVzQdW43UUN3ME2wMlAyQDV6IN88US=>	MVXTRW5ITVJ?
THP-1	NIT6TIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M33FTmlEPTB;MD6wNVk6QCEQvF2=	MU\TRW5ITVJ?
ONS-76	NU\ae2lxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3PlbmlEPTB;MD6wNlA{PiEQvF2=	NHi4cVdUSU6JRWK=
A2780	M3PKb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYHJR\|UxRTBwMEKwO\|kh\|ryP	M4\nWnNCVkeHUh?=
RPMI-2650	NE\zZ\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTnTWM2OD1yLkCyNlk3KM7:TR?=	NHHxfVZUSU6JRWK=
MEL-HO	M{XRW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3vrXmlEPTB;MD6wNlM1QCEQvF2=	NH\UUVRUSU6JRWK=
MC-CAR	NUD2NY04T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnHkTWM2OD1yLkCyN\|U3KM7:TR?=	NHPDT3RUSU6JRWK=
HSC-2	MkHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjl[mJwUUN3ME2wMlAzPDZ4IN88US=>	NIPmZ\|ZUSU6JRWK=
MEL-JUSO	NWTnSppoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MojETWM2OD1yLkCyOFc{KM7:TR?=	M{TEWXNCVkeHUh?=
CAL-62	MnG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2DVVWlEPTB;MD6wNlYxOiEQvF2=	NX\nUllFW0GQR1XS
DMS-273	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MY\JR\|UxRTBwMEK4OFch\|ryP	NELqe2FUSU6JRWK=
S-117	M{f4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2nFS2lEPTB;MD6wNlkxPiEQvF2=	MYjTRW5ITVJ?
SUP-T1	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVTCXnRVUUN3ME2wMlAzQTR7IN88US=>	MUTTRW5ITVJ?
MZ2-MEL	NXjsblR5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{LRSmlEPTB;MD6wNlk2QSEQvF2=	NF7pd\|hUSU6JRWK=
KYSE-270	MlXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MULJR\|UxRTBwMEK5O\|Yh\|ryP	NVz2N2xtW0GQR1XS
CMK	NIfpTIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwMEOwNlMh\|ryP	NU\Yc3g1W0GQR1XS
8505C	NUL5To4{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEHiXHNKSzVyPUCuNFMxPCEQvF2=	M{LSO3NCVkeHUh?=
NUGC-3	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3SwOmlEPTB;MD6wN\|A1QCEQvF2=	MmnBV2FPT0WU
A101D	NIW5VFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml74TWM2OD1yLkCzNFU2KM7:TR?=	MVTTRW5ITVJ?
G-401	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPrfoNYUUN3ME2wMlA{ODl\|IN88US=>	MWDTRW5ITVJ?
OVCAR-8	NYLqSYVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLMTWM2OD1yLkCzNVA4KM7:TR?=	NV7Rb3NHW0GQR1XS
IMR-5	NHzKRoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH73ZWdKSzVyPUCuNFMzPDRizszN	M1juPHNCVkeHUh?=
DoTc2-4510	NID1dGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Ml[xTWM2OD1yLkCzN\|k{KM7:TR?=	MWPTRW5ITVJ?
HOS	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnjwTWM2OD1yLkCzOFc{KM7:TR?=	MnTpV2FPT0WU
HEC-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2nNO2lEPTB;MD6wN\|Y5KM7:TR?=	MmLRV2FPT0WU
SW756	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGCzR3ZKSzVyPUCuNFM5OjFizszN	MUfTRW5ITVJ?
NCI-H64	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NX:wW4E4UUN3ME2wMlA{QDR{IN88US=>	MkTzV2FPT0WU
EW-16	NEDGN5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVvJR\|UxRTBwMEO5NFkh\|ryP	NFfIWIxUSU6JRWK=
CAL-51	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUfJR\|UxRTBwMESwNFUh\|ryP	NGnnVYJUSU6JRWK=
KYSE-150	NVyzN2lwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmWxTWM2OD1yLkC0NFEyKM7:TR?=	NFS1cW9USU6JRWK=
SW1710	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2CwWWlEPTB;MD6wOFAyQCEQvF2=	MVzTRW5ITVJ?
HuP-T4	NHXnRYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4PRc2lEPTB;MD6wOFEyQCEQvF2=	NHGyRlZUSU6JRWK=
LB373-MEL-D	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTmbZI1UUN3ME2wMlA1OjN{IN88US=>	MV\TRW5ITVJ?
EW-13	M2KwU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmLNTWM2OD1yLkC0OFA3KM7:TR?=	MnrTV2FPT0WU
HT-29	M3rCUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NH76XVFKSzVyPUCuNFQ1QSEQvF2=	NWLWNWltW0GQR1XS
SCC-25	M1rVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIHF[GlKSzVyPUCuNFQ1QTRizszN	MV7TRW5ITVJ?
REH	NVX6bFdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzve3VtUUN3ME2wMlA1PjN3IN88US=>	MVvTRW5ITVJ?
L-363	NIO4bmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGLDRYdKSzVyPUCuNFQ3PzlizszN	NVLqc4lRW0GQR1XS
NCI-H1770	MnLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnvXTWM2OD1yLkC0Olk4KM7:TR?=	M4rIdXNCVkeHUh?=
CHL-1	MnjnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWnTRYhCUUN3ME2wMlA1QDV5IN88US=>	NV\iU3UzW0GQR1XS
ES1	M3nlPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3fa[mlEPTB;MD6wOFg5PSEQvF2=	MlHWV2FPT0WU
SCC-15	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;UW49YUUN3ME2wMlA1QTB{IN88US=>	MYLTRW5ITVJ?
MRK-nu-1	NInxZWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFHTSWRKSzVyPUCuNFQ6OzZizszN	NUHq[lNTW0GQR1XS
PF-382	NHPGflhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUTlTI1XUUN3ME2wMlA1QTN7IN88US=>	M2HhfHNCVkeHUh?=
COLO-680N	NED5cXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLDbZZKSzVyPUCuNFUxPDdizszN	MlW3V2FPT0WU
LK-2	MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1LQU2lEPTB;MD6wOVA3OyEQvF2=	MlzGV2FPT0WU
NCI-H2342	NGL0eGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NETsT4ZKSzVyPUCuNFUyOTdizszN	Mlj3V2FPT0WU
HMV-II	NUDzeIkxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;BR5lKSzVyPUCuNFUzOzlizszN	NUixcYJzW0GQR1XS
PC-14	M{LyVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoqxTWM2OD1yLkC1NlUzKM7:TR?=	NFixUJVUSU6JRWK=
COLO-320-HSR	NYTydW5zT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwMEWyPFkh\|ryP	M4LadHNCVkeHUh?=
697	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIL6blZKSzVyPUCuNFU{OjNizszN	MXrTRW5ITVJ?
NEC8	MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXPWGZUUUN3ME2wMlA2PTlizszN	M{LmZXNCVkeHUh?=
LCLC-97TM1	M3LnN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnH4TWM2OD1yLkC1OVk1KM7:TR?=	NFvRWJlUSU6JRWK=
Daoy	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX;JR\|UxRTBwMEW2NVYh\|ryP	MmDJV2FPT0WU
ETK-1	MmjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NImyW4ZKSzVyPUCuNFU3PzJizszN	MnPWV2FPT0WU
A388	M4XjeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYHXc4FuUUN3ME2wMlA2Pjl3IN88US=>	NYfmZ48xW0GQR1XS
COLO-205	M2jwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXnJR\|UxRTBwMEW3NVYh\|ryP	M{TNNHNCVkeHUh?=
SK-PN-DW	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2PQRmlEPTB;MD6wOVczQSEQvF2=	M3rvUnNCVkeHUh?=
SF268	NHfkPYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHGwZVNKSzVyPUCuNFU4PTZizszN	MWPTRW5ITVJ?
OCI-AML2	MmPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvmZYtsUUN3ME2wMlA2Pzd5IN88US=>	MoriV2FPT0WU
GAMG	NIDqVXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYn3e4dIUUN3ME2wMlA2QCEQvF2=	M4HaZXNCVkeHUh?=
BCPAP	NW\nWm46T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mor1TWM2OD1yLkC1PFkzKM7:TR?=	MVjTRW5ITVJ?
BC-1	MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlvMTWM2OD1yLkC2NFIzKM7:TR?=	M2XKWHNCVkeHUh?=
IA-LM	M4jqc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwME[wOVMh\|ryP	NUnTS3lGW0GQR1XS
NCI-H1299	NWnET41lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NY\JT5VbUUN3ME2wMlA3OTNizszN	M4nqNXNCVkeHUh?=
COR-L23	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NH7jbFFKSzVyPUCuNFYyOzRizszN	NIn2XYFUSU6JRWK=
KYSE-180	NYS3Ro96T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XMPGlEPTB;MD6wOlE1OiEQvF2=	MVXTRW5ITVJ?
LOXIMVI	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHrDXIdKSzVyPUCuNFYyQDhizszN	MlG4V2FPT0WU
BL-41	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXLRO3g2UUN3ME2wMlA3OjF7IN88US=>	M{DW[nNCVkeHUh?=
BL-70	Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NETIdW5KSzVyPUCuNFY{ODJizszN	NXvaSWYyW0GQR1XS
NOS-1	NHXzWZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWPRV\|V[UUN3ME2wMlA3PDFzIN88US=>	MUXTRW5ITVJ?
NB13	M1fnXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MljXTWM2OD1yLkC2OFIyKM7:TR?=	Mn3aV2FPT0WU
CAL-27	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHP0VZFKSzVyPUCuNFY1PjRizszN	MY\TRW5ITVJ?
CA46	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3\odmlEPTB;MD6wOlU{PyEQvF2=	NV6wc2tLW0GQR1XS
SW962	NH7QPWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPvTWM2OD1yLkC2OVY6KM7:TR?=	MULTRW5ITVJ?
NCI-H226	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXDTWM2OD1yLkC2OlMzKM7:TR?=	M2OwS3NCVkeHUh?=
KYSE-70	NGPwclFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4nGWmlEPTB;MD6wOlk1PSEQvF2=	NXnlTnF5W0GQR1XS
Daudi	NXzvN2JoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrQZ5F{UUN3ME2wMlA4ODhzIN88US=>	NXrsSm1QW0GQR1XS
SW626	MofwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHvjWGxKSzVyPUCuNFczODRizszN	NFjoUFZUSU6JRWK=
ESS-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFXPRZdKSzVyPUCuNFczPDZizszN	NXK2b\|c2W0GQR1XS
YT	NVXBXmdNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmrwTWM2OD1yLkC3N\|Q2KM7:TR?=	NF7T[VFUSU6JRWK=
P12-ICHIKAWA	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzmTWM2OD1yLkC3N\|Q6KM7:TR?=	NVXGNJVKW0GQR1XS
BxPC-3	NHL6SnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX7JR\|UxRTBwMEe0OVgh\|ryP	M3n2OnNCVkeHUh?=
CTV-1	M{\MNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVvJR\|UxRTBwMEe1NVch\|ryP	Ml;SV2FPT0WU
MLMA	NFnyNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmLmTWM2OD1yLkC3OVM1KM7:TR?=	NVq4e2dqW0GQR1XS
WSU-NHL	NEX2UZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTSbHNKSzVyPUCuNFc2PTRizszN	NWroellTW0GQR1XS
CTB-1	MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NInzSphKSzVyPUCuNFc2QDhizszN	NVn5cYFNW0GQR1XS
MMAC-SF	NHfuS\|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF[3Z4xKSzVyPUCuNFc3PjhizszN	NHv1U4hUSU6JRWK=
8-MG-BA	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVrGVHhNUUN3ME2wMlA4QDBzIN88US=>	MVzTRW5ITVJ?
NCI-H358	NHraOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{T6UWlEPTB;MD6wO\|g4QSEQvF2=	NHe5RoJUSU6JRWK=
BFTC-905	MmWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVvtXGs4UUN3ME2wMlA4QTB7IN88US=>	NUHubHlbW0GQR1XS
NCI-H727	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWfJR\|UxRTBwMEiwOVMh\|ryP	M322WHNCVkeHUh?=
CHP-212	NXS2c2RXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3S0TWlEPTB;MD6wPFA6PSEQvF2=	MWPTRW5ITVJ?
HOP-62	NWCzU5FQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mm\aTWM2OD1yLkC4NlQ2KM7:TR?=	M4nNfHNCVkeHUh?=
CESS	M3[zfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1vmZWlEPTB;MD6wPFI3QSEQvF2=	Mni4V2FPT0WU
HuCCT1	NFzzS4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoTyTWM2OD1yLkC4N\|M{KM7:TR?=	MnHqV2FPT0WU
DEL	M{\wbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mmr0TWM2OD1yLkC4N\|Q4KM7:TR?=	MY\TRW5ITVJ?
5637	NVq0W4ZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkjLTWM2OD1yLkC4N\|Y4KM7:TR?=	NVm2SWxWW0GQR1XS
RS4-11	NGfUN2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MW\JR\|UxRTBwMEi0PVch\|ryP	NWPPeWs3W0GQR1XS
KURAMOCHI	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MofoTWM2OD1yLkC4OVA6KM7:TR?=	MU\TRW5ITVJ?
A427	NEj0VZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHC[HlwUUN3ME2wMlA5PTF{IN88US=>	M162[nNCVkeHUh?=
A3-KAW	NEW4d3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn:1TWM2OD1yLkC4OVY3KM7:TR?=	NVr2U2lDW0GQR1XS
LS-123	MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHTUXJKSzVyPUCuNFg4OTlizszN	M{TQPHNCVkeHUh?=
LoVo	NEHZe3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXezWnB5UUN3ME2wMlA5PzJizszN	MXrTRW5ITVJ?
PA-1	MkHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoXXTWM2OD1yLkC4O\|Y6KM7:TR?=	Mn3DV2FPT0WU
CP50-MEL-B	Mn7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHLwSG5KSzVyPUCuNFg4QTNizszN	MUnTRW5ITVJ?
A431	MlTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mm\sTWM2OD1yLkC4PFAyKM7:TR?=	NIXJNWJUSU6JRWK=
HCT-116	NVPxO2EzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MY\JR\|UxRTBwMEi4NFIh\|ryP	M{X5T3NCVkeHUh?=
A4-Fuk	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVHGSmFyUUN3ME2wMlA5QTR5IN88US=>	NH;qOWxUSU6JRWK=
RPMI-6666	Mn\JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmrmTWM2OD1yLkC4PVY4KM7:TR?=	MmrlV2FPT0WU
Calu-6	Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoC0TWM2OD1yLkC5NFI6KM7:TR?=	Mn\OV2FPT0WU
KMOE-2	NV;ucHlOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYXJR\|UxRTBwMEmwN\|kh\|ryP	M4r0VXNCVkeHUh?=
A704	M1LyTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{HwSmlEPTB;MD6wPVE2KM7:TR?=	MXfTRW5ITVJ?
HO-1-N-1	NIT4c\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M122ZmlEPTB;MD6wPVI1QSEQvF2=	M4fQdXNCVkeHUh?=
NCI-H2122	M1jiU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPjTWNOUUN3ME2wMlA6Ozd6IN88US=>	NHTZPGhUSU6JRWK=
U-698-M	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUXYO2hoUUN3ME2wMlA6PDB7IN88US=>	NGnZSmNUSU6JRWK=
IST-SL2	NFXkenNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHnZemhKSzVyPUCuNFk1PjhizszN	MnzXV2FPT0WU
TE-10	Ml3mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlPJTWM2OD1yLkC5OVg1KM7:TR?=	M1fjfXNCVkeHUh?=
PANC-03-27	M3vndWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4n5dWlEPTB;MD6wPVY4OSEQvF2=	Ml3HV2FPT0WU
KYSE-410	NYrzfINwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTBwMEm3PVch\|ryP	NGXUeVhUSU6JRWK=
TE-8	NX;KZWhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MULJR\|UxRTBwMEm4PFUh\|ryP	NVzXcWVwW0GQR1XS
MN-60	NHrl[lZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGHNZ25KSzVyPUCuNFk5QTdizszN	NYjnfWI4W0GQR1XS
NCI-H460	NWrONFRRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWW2XWJvUUN3ME2wMlExODlizszN	MoXHV2FPT0WU
LB771-HNC	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LNN2lEPTB;MD6xNFI2PSEQvF2=	M{DPd3NCVkeHUh?=
ES4	NF\pfYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3S3OGlEPTB;MD6xNFI3PCEQvF2=	MVjTRW5ITVJ?
HUTU-80	NHLBRmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwMUCzOlUh\|ryP	NFr4b4dUSU6JRWK=
647-V	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYP6[FU1UUN3ME2wMlExPDB6IN88US=>	M3mxZXNCVkeHUh?=
HTC-C3	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXTEdlA2UUN3ME2wMlExPDN{IN88US=>	NX;GenNTW0GQR1XS
NTERA-S-cl-D1	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGPqXXRKSzVyPUCuNVA1PDhizszN	M{jPZnNCVkeHUh?=
A2058	M4m2[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojSTWM2OD1yLkGwOlU2KM7:TR?=	NWrOOXFCW0GQR1XS
MZ1-PC	NVXtOlE1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHXV[ZdKSzVyPUCuNVA5OyEQvF2=	MYrTRW5ITVJ?
J82	Mn:2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYHpSXlqUUN3ME2wMlExQDh2IN88US=>	NYT1ZW8yW0GQR1XS
ARH-77	MlfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Ml7FTWM2OD1yLkGxJO69VQ>?	M2[yOHNCVkeHUh?=
Ca9-22	M{TTNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVjJR\|UxRTBwMUGxNlgh\|ryP	M16wXHNCVkeHUh?=
NCI-H1648	NXTv[HBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF;lUZZKSzVyPUCuNVEzQDZizszN	M4PBNHNCVkeHUh?=
MC116	MoTKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfSTWM2OD1yLkGxN\|M4KM7:TR?=	M3jhPHNCVkeHUh?=
EoL-1-cell	M4rKWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUHJR\|UxRTBwMUG0Olch\|ryP	MnLKV2FPT0WU
PANC-10-05	NVTINVJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4PZ[GlEPTB;MD6xNVQ6OSEQvF2=	MYPTRW5ITVJ?
SF539	NFnqT4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTGdYhKSzVyPUCuNVE3OTZizszN	Moj1V2FPT0WU
ES8	MlK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4DjR2lEPTB;MD6xNVY{OyEQvF2=	M{TqNXNCVkeHUh?=
NCI-H810	MlLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{[x[WlEPTB;MD6xNVY3PCEQvF2=	MlvzV2FPT0WU
J-RT3-T3-5	MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1zV[GlEPTB;MD6xNVc2KM7:TR?=	NEGzZlNUSU6JRWK=
NY	MlfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnTHTWM2OD1yLkGxPFE4KM7:TR?=	NWPHTpNsW0GQR1XS
NCI-SNU-1	NVHHdGdCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX7oW5lxUUN3ME2wMlEzOTR6IN88US=>	NX\zVIdPW0GQR1XS
EFM-19	Mk[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M13XXGlEPTB;MD6xNlM4PCEQvF2=	NHTOVI5USU6JRWK=
HCC1806	NFm4[ItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4\TUWlEPTB;MD6xNlM5OyEQvF2=	MknpV2FPT0WU
HCE-T	NXXheFMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWfJR\|UxRTBwMUK1N\|Eh\|ryP	MoTGV2FPT0WU
HT-1376	Ml\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlK4TWM2OD1yLkGyOlY5KM7:TR?=	MUXTRW5ITVJ?
BE-13	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmD2TWM2OD1yLkGyPFY3KM7:TR?=	MUHTRW5ITVJ?
NCI-H520	NIrOdlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGTPOnNKSzVyPUCuNVI5PjdizszN	M{nsT3NCVkeHUh?=
SK-MES-1	MorsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXG5Z3FvUUN3ME2wMlEzQTF\|IN88US=>	NYj0VIJGW0GQR1XS
SNU-423	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MmTqTWM2OD1yLkGyPVE1KM7:TR?=	NITEXWhUSU6JRWK=
Ramos-2G6-4C10	NXT4[ZpqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWTocpRjUUN3ME2wMlEzQTF4IN88US=>	M{nTOnNCVkeHUh?=
EW-18	NELVZ3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvqTWM2OD1yLkGzNFI3KM7:TR?=	M4j3RXNCVkeHUh?=
NCI-H2087	NH3WTVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTBwMUOwNlch\|ryP	MkXQV2FPT0WU
COLO-792	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWrJR\|UxRTBwMUOxOlUh\|ryP	MYLTRW5ITVJ?
QIMR-WIL	Mn3nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2fFXGlEPTB;MD6xN\|IzOyEQvF2=	MkLOV2FPT0WU
ACHN	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTBwMUOyOFch\|ryP	NXT6d3FYW0GQR1XS
RPMI-8866	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIXiUG5KSzVyPUCuNVMzPjFizszN	MmTtV2FPT0WU
SK-LU-1	NULle49sT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkS5TWM2OD1yLkGzOFQ6KM7:TR?=	MVPTRW5ITVJ?
SK-UT-1	M1\rS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPBfZNKSzVyPUCuNVM3OjhizszN	NXzvU3RQW0GQR1XS
MFE-296	NXfDO2pzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVzYNJFTUUN3ME2wMlE{QDZ2IN88US=>	M4X6R3NCVkeHUh?=
RD	MkjES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4j4ZmlEPTB;MD6xN\|k6PyEQvF2=	NVPCcXlqW0GQR1XS
LS-411N	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYPJR\|UxRTBwMUSyPVUh\|ryP	MYPTRW5ITVJ?
NCI-H747	M2X0fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3HTWM2OD1yLkG0N{DPxE1?	M1rVe3NCVkeHUh?=
ES6	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYrJR\|UxRTBwMUSzOkDPxE1?	NIewdHRUSU6JRWK=
TE-1	NHKyXpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWfQ[GNkUUN3ME2wMlE1PDB5IN88US=>	M2q4NnNCVkeHUh?=
SJSA-1	NH3vOFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmL1TWM2OD1yLkG0O\|A4KM7:TR?=	MYPTRW5ITVJ?
NCI-H1355	MljoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4fyUGlEPTB;MD6xOVI6OyEQvF2=	MUfTRW5ITVJ?
HEL	M{X2U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1zUPGlEPTB;MD6xOVQ1PyEQvF2=	M1mz[3NCVkeHUh?=
639-V	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXzJR\|UxRTBwMUW1PVYh\|ryP	MlK5V2FPT0WU
AN3-CA	Mnn0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXTJR\|UxRTBwMUW2N\|kh\|ryP	NEfVXlBUSU6JRWK=
SK-MEL-2	M1WyXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFX3[YVKSzVyPUCuNVU3PjhizszN	MkG0V2FPT0WU
SW872	NYLIVVg3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTiTWM2OD1yLkG2NFQzKM7:TR?=	MVTTRW5ITVJ?
DU-4475	NVW5Z5g1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MW\JR\|UxRTBwMU[xOlIh\|ryP	MnLaV2FPT0WU
YKG-1	M3\s[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVHJR\|UxRTBwMU[yO\|Mh\|ryP	NVzONVY{W0GQR1XS
GT3TKB	M1HUPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfNUYdKSzVyPUCuNVYzQDNizszN	MW\TRW5ITVJ?
GB-1	NVG4bFA5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NELWcmVKSzVyPUCuNVY1OjRizszN	NY\hUXhQW0GQR1XS
KARPAS-422	NHvGVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn7CTWM2OD1yLkG2OVc1KM7:TR?=	MUfTRW5ITVJ?
ATN-1	M2HMSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWfJR\|UxRTBwMU[2OVYh\|ryP	NGPS[opUSU6JRWK=
HLE	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWDRdJhTUUN3ME2wMlE3QDd5IN88US=>	MX;TRW5ITVJ?
D-542MG	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYnJR\|UxRTBwMU[5PFYh\|ryP	MXTTRW5ITVJ?
EB-3	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEPHO\|VKSzVyPUCuNVc{OSEQvF2=	NUfGPYpIW0GQR1XS
HCC1143	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPUSGR{UUN3ME2wMlE4Ozl4IN88US=>	NHzk[IFUSU6JRWK=
DJM-1	M{fadWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIf4UHdKSzVyPUCuNVc1PTFizszN	NXrpRms4W0GQR1XS
BT-474	NVzqOm1bT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnLoTWM2OD1yLkG3OFg6KM7:TR?=	NHPNemtUSU6JRWK=
BB65-RCC	NVz1SnFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYHJR\|UxRTBwMUe1OFUh\|ryP	MnfSV2FPT0WU
NCI-H292	NXfU[WNTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoC1TWM2OD1yLkG3OlAyKM7:TR?=	NV;DTINyW0GQR1XS
MKN28	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XROmlEPTB;MD6xO\|Y2OyEQvF2=	MV7TRW5ITVJ?
TK10	Mn36S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVTlVm9pUUN3ME2wMlE4PzB{IN88US=>	NWLqSYd3W0GQR1XS
TYK-nu	NHTDflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXXJR\|UxRTBwMUe5OFkh\|ryP	MlW1V2FPT0WU
8305C	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXKzZpd7UUN3ME2wMlE4QTdzIN88US=>	MX\TRW5ITVJ?
MV-4-11	Mn;qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHWXFlKSzVyPUCuNVc6PzdizszN	NVHxWVAxW0GQR1XS
NCI-H522	MnzZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M37mO2lEPTB;MD6xPFA6PCEQvF2=	NGCyU4JUSU6JRWK=
Hs-578-T	M2TSW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV7OXllSUUN3ME2wMlE5Ojl{IN88US=>	Ml7EV2FPT0WU
LCLC-103H	NF6yS45Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX\JR\|UxRTBwMUi1Nlch\|ryP	MnXOV2FPT0WU
MHH-ES-1	NXPHNIc6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXnJR\|UxRTBwMUi2Nlkh\|ryP	Ml3QV2FPT0WU
NCI-H441	M3\pbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{T4d2lEPTB;MD6xPVE1QCEQvF2=	NYr5Wm1YW0GQR1XS
AM-38	M4jBOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPTSWdbUUN3ME2wMlE6OjJ3IN88US=>	NGTWR5dUSU6JRWK=
SW1783	NIrhZlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTBwMUmzNFUh\|ryP	MkPIV2FPT0WU
SK-HEP-1	NHzycIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M{TVeWlEPTB;MD6xPVY{PyEQvF2=	NELK[o5USU6JRWK=
OAW-28	NUfFVo5QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGfJeFJKSzVyPUCuNlAyPzhizszN	M3y1fXNCVkeHUh?=
TE-15	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYW4WFJsUUN3ME2wMlIxOjV{IN88US=>	MknBV2FPT0WU
HCE-4	M1XzSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnLjTWM2OD1yLkKwNlg1KM7:TR?=	NEDlRodUSU6JRWK=
JiyoyeP-2003	MlHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4n1WGlEPTB;MD6yNFM{PiEQvF2=	M{fNWnNCVkeHUh?=
OVCAR-4	NGLSPY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYL6[YhSUUN3ME2wMlIxPjJ6IN88US=>	Ml\nV2FPT0WU
SNU-449	M3q0Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn2zTWM2OD1yLkKwO\|k4KM7:TR?=	NYDCNHE3W0GQR1XS
SBC-5	MorrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwMkGyNVUh\|ryP	NFSyN\|NUSU6JRWK=
T84	M2\hPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWTJR\|UxRTBwMkGyOFgh\|ryP	NHexNXZUSU6JRWK=
LP-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3;0N2lEPTB;MD6yNVMxOiEQvF2=	MoXUV2FPT0WU
MG-63	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlLOTWM2OD1yLkKxN\|gzKM7:TR?=	M4\Fc3NCVkeHUh?=
OAW-42	NXH0VG9{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVOzfIs2UUN3ME2wMlIyPDd6IN88US=>	MVrTRW5ITVJ?
L-540	NUHnWopDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnnQTWM2OD1yLkKxOVk5KM7:TR?=	MXLTRW5ITVJ?
RH-1	Ml32S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXvETGxuUUN3ME2wMlIzOjR{IN88US=>	NYXXVG9JW0GQR1XS
HCT-15	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlfWTWM2OD1yLkKyOFg1KM7:TR?=	MnruV2FPT0WU
OCUB-M	NHS4eXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVm5WW42UUN3ME2wMlIzPDh6IN88US=>	MkLhV2FPT0WU
GP5d	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2i2XmlEPTB;MD6yNlUzQCEQvF2=	M3;te3NCVkeHUh?=
NCI-H2030	NVfF[YJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NYrIS5dZUUN3ME2wMlIzPzN2IN88US=>	NIH0RYlUSU6JRWK=
ML-2	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYj4UG9DUUN3ME2wMlIzQDh7IN88US=>	MYrTRW5ITVJ?
CAL-39	NUW0N283T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NIm4XVNKSzVyPUCuNlI6OzZizszN	NELCWlNUSU6JRWK=
MIA-PaCa-2	NULKW21KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NGKzS5BKSzVyPUCuNlMzQDdizszN	NWjK[FM4W0GQR1XS
TE-9	NV\QO5FZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnWzTWM2OD1yLkKzN\|Ih\|ryP	Mn21V2FPT0WU
LB2518-MEL	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVnaeWJnUUN3ME2wMlI{Ozd{IN88US=>	MUPTRW5ITVJ?
DB	NYrLTWhLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkewTWM2OD1yLkKzOFM5KM7:TR?=	MWjTRW5ITVJ?
NCI-H596	NYLqV\|ZVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmK3TWM2OD1yLkKzOVcyKM7:TR?=	MUjTRW5ITVJ?
SW1990	MmXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1fKb2lEPTB;MD6yN\|k1PiEQvF2=	MoPwV2FPT0WU
P30-OHK	NVntbWZZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwMkSwOUDPxE1?	M3n6RXNCVkeHUh?=
ALL-PO	NFLhWnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mm[0TWM2OD1yLkK0NVY6KM7:TR?=	NYi0dW5TW0GQR1XS
Saos-2	MonIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTBwMkS1O\|Eh\|ryP	NWq1bIFTW0GQR1XS
MFH-ino	NITYUnJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NID4eGJKSzVyPUCuNlQ3QTJizszN	MUXTRW5ITVJ?
OE33	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4XFc2lEPTB;MD6yOVEyKM7:TR?=	NICwZ\|ZUSU6JRWK=
Calu-3	Mn70S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFTRendKSzVyPUCuNlUzQTdizszN	M3rjO3NCVkeHUh?=
HT	MkjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2GwT2lEPTB;MD6yOVYzOSEQvF2=	M1PlU3NCVkeHUh?=
LXF-289	MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUXJR\|UxRTBwMkW5PFQh\|ryP	MlzlV2FPT0WU
KGN	M1n4cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3JTWM2OD1yLkK2NFg6KM7:TR?=	MVrTRW5ITVJ?
NCI-H1417	MlS0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUjJR\|UxRTBwMk[1NlQh\|ryP	M4DUWnNCVkeHUh?=
SF126	M4P4SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{izemlEPTB;MD6yO\|MxOiEQvF2=	NXnQUZh7W0GQR1XS
SAS	MkHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoH0TWM2OD1yLkK3N\|A5KM7:TR?=	MV\TRW5ITVJ?
22RV1	NHi2dHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXPJR\|UxRTBwMkezO\|gh\|ryP	M1zNdnNCVkeHUh?=
GI-1	NHjONo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NE\heIVKSzVyPUCuNlc1QDdizszN	NU\3WYEzW0GQR1XS
ES3	NGS3OVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVPJR\|UxRTBwMke3OlMh\|ryP	M3jZdXNCVkeHUh?=
NB1	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{CyZWlEPTB;MD6yO\|g4PiEQvF2=	MXzTRW5ITVJ?
NCI-H650	NWPuTZN4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlLWTWM2OD1yLkK4N\|AzKM7:TR?=	MXzTRW5ITVJ?
IST-MES1	MlfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MonTTWM2OD1yLkK4OVU1KM7:TR?=	NYT4WItlW0GQR1XS
UM-UC-3	NGHIfpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHPpTJZKSzVyPUCuNlkyPCEQvF2=	NUj3UlhyW0GQR1XS
CAL-120	M4HWSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4jNWGlEPTB;MD6yPVY{OSEQvF2=	M{TJU3NCVkeHUh?=
UACC-62	NETre5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTBwM{CyOFEh\|ryP	NYLtfZlnW0GQR1XS
TE-11	NXzhTYo5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFzmTXdKSzVyPUCuN\|AzPDlizszN	M{fSSHNCVkeHUh?=
MKN1	MmPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoWzTWM2OD1yLkOwN\|Yh\|ryP	NWTFRZpSW0GQR1XS
KS-1	NXHTfFA1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTBwM{C1NlYh\|ryP	MVXTRW5ITVJ?
GCIY	NYrTcGZ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Ml7jTWM2OD1yLkOxNFAzKM7:TR?=	MVrTRW5ITVJ?
OVCAR-5	NFfDT2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXqboZKSzVyPUCuN\|EyODZizszN	NYHWW21GW0GQR1XS
U-266	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NV;OdphRUUN3ME2wMlMyOTR5IN88US=>	M4rEN3NCVkeHUh?=
Calu-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NIDGbWxKSzVyPUCuN\|EzQDlizszN	MYfTRW5ITVJ?
SK-LMS-1	MnfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVzJR\|UxRTBwM{G0Nlkh\|ryP	MmjFV2FPT0WU
COLO-741	Ml\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TrVWlEPTB;MD6zNVYyPCEQvF2=	NWnMfWkyW0GQR1XS
RPMI-8226	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2\iR2lEPTB;MD6zNVY1OSEQvF2=	NXjONWg4W0GQR1XS
KM12	NGHPZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwM{G4N{DPxE1?	MYDTRW5ITVJ?
NMC-G1	NHH3O49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFPXXZZKSzVyPUCuN\|E5PiEQvF2=	NFrBNpVUSU6JRWK=
SJRH30	NULLV\|RyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MWXJR\|UxRTBwM{KwOVIh\|ryP	M3u5SXNCVkeHUh?=
COR-L105	NG[zT3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWftT2VJUUN3ME2wMlMzOjF6IN88US=>	MYLTRW5ITVJ?
IM-9	M2LSRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M37GfGlEPTB;MD6zN\|AzOSEQvF2=	M4nubnNCVkeHUh?=
TE-12	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{H5Z2lEPTB;MD6zN\|MyPyEQvF2=	MYrTRW5ITVJ?
KG-1	Mne0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzvTWM2OD1yLkOzOFMzKM7:TR?=	Mmm3V2FPT0WU
U251	M3fFcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTBwM{O0OVYh\|ryP	NFTpTVZUSU6JRWK=
EFO-27	NUjTdFFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3XXTWlEPTB;MD6zN\|k2OSEQvF2=	NYXzZ3FkW0GQR1XS
EW-24	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYrhcXZnUUN3ME2wMlM{QTh2IN88US=>	NEnUdoVUSU6JRWK=
SF295	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLWTWM2OD1yLkOzPVk6KM7:TR?=	M2XHW3NCVkeHUh?=
MC-IXC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkfTTWM2OD1yLkO0OUDPxE1?	MU\TRW5ITVJ?
NCI-H2405	M{i1[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1XvWmlEPTB;MD6zOFc{OiEQvF2=	NUDCb\|F[W0GQR1XS
NCI-H2009	M2\hT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M1\TW2lEPTB;MD6zOFc{QSEQvF2=	M13UU3NCVkeHUh?=
LB1047-RCC	NVP1TFloT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NHraXHVKSzVyPUCuN\|U5OTVizszN	MlHDV2FPT0WU
KNS-81-FD	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWK2Vpl[UUN3ME2wMlM3PjZ5IN88US=>	M1XMZnNCVkeHUh?=
HOP-92	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUnH[XExUUN3ME2wMlM3QDNizszN	MkTXV2FPT0WU
L-428	M1TnbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3jtfmlEPTB;MD6zO\|AyPiEQvF2=	NYrifoxMW0GQR1XS
C3A	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NET2d41KSzVyPUCuN\|c{PzlizszN	NGTwNY1USU6JRWK=
NCI-H1792	M2TufWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXfJR\|UxRTBwM{e2OVUh\|ryP	NFfoT2ZUSU6JRWK=
HuH-7	NXjIdoVuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEntfG1KSzVyPUCuN\|c6OSEQvF2=	M13k[HNCVkeHUh?=
AGS	NXHubGF4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXXJR\|UxRTBwM{i2N\|gh\|ryP	M4LrTHNCVkeHUh?=
HT-1197	MnzNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGnJPVZKSzVyPUCuN\|k1PiEQvF2=	MYDTRW5ITVJ?
CGTH-W-1	NVXvXnpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2HTT2lEPTB;MD6zPVkyOyEQvF2=	NWW3fHhsW0GQR1XS
KNS-42	MoKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\rOGM{UUN3ME2wMlQxODR3IN88US=>	NH63NlZUSU6JRWK=
HuO-3N1	M{\4UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MY\JR\|UxRTBwNECwOVUh\|ryP	NI\ZeIRUSU6JRWK=
VMRC-RCZ	NFW4eldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4D6dmlEPTB;MD60NFMxOyEQvF2=	M1;ZdnNCVkeHUh?=
SW954	M3nxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\MdmNKSzVyPUCuOFA{OzVizszN	M{DSN3NCVkeHUh?=
MES-SA	MkWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWLaUHB[UUN3ME2wMlQxPTB3IN88US=>	MYXTRW5ITVJ?
Ca-Ski	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFLVd41KSzVyPUCuOFA2OjRizszN	MlTXV2FPT0WU
SW13	NFrzN2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWfJR\|UxRTBwNEC2NlYh\|ryP	NITxZZJUSU6JRWK=
NCI-H1437	NVLsOZZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmmzTWM2OD1yLkSwPFA2KM7:TR?=	NUTNelByW0GQR1XS
U-118-MG	MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlT2TWM2OD1yLkSwPVA1KM7:TR?=	NVTGVFh6W0GQR1XS
NCI-H1734	NEPNe3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXjkcVFlUUN3ME2wMlQzODF\|IN88US=>	NE\sTXJUSU6JRWK=
HDLM-2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPuXVVmUUN3ME2wMlQzODN\|IN88US=>	NX;qSYxsW0GQR1XS
AU565	NEL2N2dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3XhbWlEPTB;MD60NlQ3QCEQvF2=	M4D4OHNCVkeHUh?=
FADU	MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn;6TWM2OD1yLkSyOlQ6KM7:TR?=	MVjTRW5ITVJ?
OS-RC-2	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkLWTWM2OD1yLkSzNFg{KM7:TR?=	NH\MUWpUSU6JRWK=
CAMA-1	MoS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnH6TWM2OD1yLkSzOlI3KM7:TR?=	MYrTRW5ITVJ?
MONO-MAC-6	MmWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1XPS2lEPTB;MD60N\|g1QSEQvF2=	M4LaXXNCVkeHUh?=
LB831-BLC	M4raWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVLJR\|UxRTBwNESzO\|Eh\|ryP	Mnz1V2FPT0WU
SW982	NE\JdXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUPJR\|UxRTBwNES1Nlgh\|ryP	M3vo[HNCVkeHUh?=
SCC-3	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnzKTWM2OD1yLkS0OVc6KM7:TR?=	NH3OVJFUSU6JRWK=
C32	NH3QbYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVe5b5pbUUN3ME2wMlQ2OjJ7IN88US=>	MYrTRW5ITVJ?
BFTC-909	NVq2S4ZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{\IZmlEPTB;MD60OVI6QSEQvF2=	Mn;jV2FPT0WU
MEG-01	NWDDVHpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXnSPWNKUUN3ME2wMlQ2Ozd\|IN88US=>	MWTTRW5ITVJ?
M14	NUnG[YhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYnJR\|UxRTBwNEW5O\|kh\|ryP	NUPyT5V6W0GQR1XS
MPP-89	NV:yNZJwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmjpTWM2OD1yLkS2NlU3KM7:TR?=	NETHV5BUSU6JRWK=
HCC1937	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXPsNZF[UUN3ME2wMlQ3Ozh2IN88US=>	NFPWRnBUSU6JRWK=
SW837	M1jLZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHnCR3VKSzVyPUCuOFY4OjJizszN	M3;2bnNCVkeHUh?=
DU-145	M4i5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHzU[oZKSzVyPUCuOFY4OjlizszN	NEHjTFNUSU6JRWK=
LB996-RCC	NFHrTFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVrJR\|UxRTBwNEewOVQh\|ryP	MYLTRW5ITVJ?
C8166	NGXwO2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTBwNEe0JO69VQ>?	Mn32V2FPT0WU
MOLT-4	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEjmPWpKSzVyPUCuOFc4OzRizszN	Mm\BV2FPT0WU
DMS-53	Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTBwNEe4NFkh\|ryP	NFHJZ5ZUSU6JRWK=
TE-5	NWGxdFZDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MmTYTWM2OD1yLkS4N\|A2KM7:TR?=	MlHMV2FPT0WU
KYSE-520	M1vQRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkLoTWM2OD1yLkS4N\|Q{KM7:TR?=	NHzpV2lUSU6JRWK=
Detroit562	MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{TCUmlEPTB;MD60PFg3KM7:TR?=	MYrTRW5ITVJ?
SIMA	NHXkcIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MU\JR\|UxRTBwNEm0NVch\|ryP	NF\hbWNUSU6JRWK=
NCI-H1651	NWjp[m1ZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3TFbGlEPTB;MD60PVY4KM7:TR?=	NHm1NG9USU6JRWK=
HCC1599	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlX4TWM2OD1yLkS5PVU2KM7:TR?=	MoriV2FPT0WU
ABC-1	NWDoSJBKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\kW2d[UUN3ME2wMlUxPDl4IN88US=>	MWXTRW5ITVJ?
CAL-33	Mm\oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYXJR\|UxRTBwNUC4OFQh\|ryP	NXjXTo9UW0GQR1XS
OPM-2	M1G0[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVzUVo9PUUN3ME2wMlUxQTN5IN88US=>	M4\SNXNCVkeHUh?=
RPMI-7951	NXHOXYRrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWrKRmhQUUN3ME2wMlUxQTV5IN88US=>	MYfTRW5ITVJ?
HT-1080	NYi4Rnp1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkDqTWM2OD1yLkWxNVE6KM7:TR?=	NWrJTWhPW0GQR1XS
LC4-1	NXrWe3NLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLHSVE2UUN3ME2wMlUyPDB\|IN88US=>	M{\TU3NCVkeHUh?=
OVCAR-3	M1KwN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVTJR\|UxRTBwNUG1O{DPxE1?	NUPKOmJEW0GQR1XS
CAPAN-1	MlHmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XOXWlEPTB;MD61NlI5QCEQvF2=	NVnPXHp7W0GQR1XS
SK-OV-3	NYPs[VU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX;DR21HUUN3ME2wMlUzPDN2IN88US=>	M2f2N3NCVkeHUh?=
HuP-T3	NXXsPJJQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4DjU2lEPTB;MD61NlgzPyEQvF2=	NIDyNmlUSU6JRWK=
NCI-H838	NEC0RZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MVjJR\|UxRTBwNUK4OFkh\|ryP	MlPmV2FPT0WU
K5	M{[zWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mm\JTWM2OD1yLkWzNlAyKM7:TR?=	NUmwNmtTW0GQR1XS
CAL-72	M1PRWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3LJSWlEPTB;MD61N\|M5PyEQvF2=	NHPmO5VUSU6JRWK=
NH-12	M3;DNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWXJR\|UxRTBwNUO5OVkh\|ryP	MXLTRW5ITVJ?
SNB75	NELFS5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NULsOFN4UUN3ME2wMlU2PzNizszN	NIPvc3dUSU6JRWK=
BPH-1	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVjJR\|UxRTBwNU[zOFQh\|ryP	MUfTRW5ITVJ?
NOMO-1	NVXCd5RWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknrTWM2OD1yLkW2N\|czKM7:TR?=	MlPaV2FPT0WU
G-402	NUL3RpRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mki3TWM2OD1yLkW2OFk6KM7:TR?=	MXLTRW5ITVJ?
NCI-H2052	MnLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mme1TWM2OD1yLkW2O\|QyKM7:TR?=	M4f1cHNCVkeHUh?=
RCM-1	NVzNUGtTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MoftTWM2OD1yLkW3NVY3KM7:TR?=	NYrVfXdbW0GQR1XS
COR-L279	MkfSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2XMb2lEPTB;MD61O\|E5PSEQvF2=	MoS3V2FPT0WU
A253	MlWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3Ps[WlEPTB;MD61O\|UzPSEQvF2=	Mnu0V2FPT0WU
SK-MM-2	Mnv6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2TTT2lEPTB;MD61O\|Y4QSEQvF2=	NXPOeY82W0GQR1XS
NCI-H1703	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlPGTWM2OD1yLkW5OFI4KM7:TR?=	MYnTRW5ITVJ?
UACC-257	NFrOSlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoLUTWM2OD1yLkW5OFg4KM7:TR?=	M4HaNnNCVkeHUh?=
KALS-1	NH7Ne3BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV\2bpFXUUN3ME2wMlYxODFzIN88US=>	NETkd5pUSU6JRWK=
ES5	MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVLSZm5uUUN3ME2wMlYxPDhizszN	NGTJ[4lUSU6JRWK=
MHH-CALL-2	M1zCcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnP3TWM2OD1yLk[wPFg5KM7:TR?=	NYjGfFl3W0GQR1XS
ChaGo-K-1	M4D4dGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFXDPVZKSzVyPUCuOlEzOjlizszN	NX;mRoRIW0GQR1XS
TGBC1TKB	NIfTd21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnMd41KSzVyPUCuOlE6QCEQvF2=	M3TzRXNCVkeHUh?=
KU-19-19	M4faTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXjEfmUzUUN3ME2wMlY1PTh4IN88US=>	M2OyWXNCVkeHUh?=
COLO-684	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGrnXo1KSzVyPUCuOlU3OTFizszN	MkXMV2FPT0WU
LS-1034	Mn\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmjLTWM2OD1yLk[1PFE6KM7:TR?=	NGXxVndUSU6JRWK=
RT-112	NWnncIN[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkTSTWM2OD1yLk[2OVg4KM7:TR?=	Mlr1V2FPT0WU
Capan-2	NEjkcYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXHnfG9WUUN3ME2wMlY3PjJ{IN88US=>	NXXwZldvW0GQR1XS
HSC-4	NXrkcY9LT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3;WPGlEPTB;MD62OlY6QCEQvF2=	NWnrUZJuW0GQR1XS
COLO-824	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3jB[GlEPTB;MD62O\|gzOyEQvF2=	NUjuS3lMW0GQR1XS
NCI-H2170	NFnQNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2ruPGlEPTB;MD62PFI2QCEQvF2=	MVPTRW5ITVJ?
GDM-1	NUDrR4VrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NULjTXo4UUN3ME2wMlY5PDl2IN88US=>	M1Pwb3NCVkeHUh?=
KP-4	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mo\QTWM2OD1yLk[5OVc{KM7:TR?=	MVPTRW5ITVJ?
VA-ES-BJ	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPJTWM2OD1yLk[5PVg3KM7:TR?=	MnroV2FPT0WU
KM-H2	NFHhWWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXjJR\|UxRTBwN{CwPVEh\|ryP	NY\0dll1W0GQR1XS
HH	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEDJVo5KSzVyPUCuO\|A3PjJizszN	MlTnV2FPT0WU
DK-MG	NWH2Zpc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{Xr[mlEPTB;MD63NVAyPiEQvF2=	NXPGZVJCW0GQR1XS
VM-CUB-1	M2rON2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmmwTWM2OD1yLkexNlU6KM7:TR?=	MXHTRW5ITVJ?
COLO-829	M2fLVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkPGTWM2OD1yLkexPVg2KM7:TR?=	MVTTRW5ITVJ?
OMC-1	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXjieGJZUUN3ME2wMlczOTB2IN88US=>	NXn5U5VEW0GQR1XS
NB12	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHXndHJKSzVyPUCuO\|I2ODRizszN	MW\TRW5ITVJ?
NCI-H28	M3\yVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV\xNJAxUUN3ME2wMlc1ODh\|IN88US=>	M1\FUHNCVkeHUh?=
A673	NXj3Xm9nT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1y4WGlEPTB;MD63OVE4PyEQvF2=	NEe0PIhUSU6JRWK=
LB2241-RCC	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGric4ZKSzVyPUCuO\|YxQDdizszN	NFW1cmJUSU6JRWK=
CCRF-CEM	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NWnPT3JuUUN3ME2wMlc4ODV{IN88US=>	MVrTRW5ITVJ?
NCI-H510A	MoewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlexTWM2OD1yLke3NVg3KM7:TR?=	MVzTRW5ITVJ?
SW48	Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIe4eVJKSzVyPUCuO\|c{OzNizszN	MYLTRW5ITVJ?
NCI-H2081	M{e4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFnuNpZKSzVyPUCuO\|gyPDdizszN	M4rEW3NCVkeHUh?=
RMG-I	M2fFdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4LKXGlEPTB;MD63PFIyOiEQvF2=	MlTiV2FPT0WU
LU-99A	NWrL[llxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1LzOmlEPTB;MD63PFQyOyEQvF2=	NVLhd5ZvW0GQR1XS
KP-N-YS	MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV\oeYNvUUN3ME2wMlc5QTJzIN88US=>	NX3ocmVWW0GQR1XS
MDA-MB-231	M4H2dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\JfJd6UUN3ME2wMlgxOTNzIN88US=>	NHLm[JpUSU6JRWK=
U031	M1vIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mk\ITWM2OD1yLkixOFI{KM7:TR?=	MojaV2FPT0WU
EVSA-T	NULqV5RKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFLrOlNKSzVyPUCuPFE3PzJizszN	MW\TRW5ITVJ?
MDA-MB-157	NVzkcnpJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEj6dFdKSzVyPUCuPFIzPzFizszN	MWjTRW5ITVJ?
EHEB	NH;WN4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYHoO\|h2UUN3ME2wMlgzOjd4IN88US=>	NGq1Z\|RUSU6JRWK=
KINGS-1	MmDkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlzyTWM2OD1yLkiyOVU2KM7:TR?=	M{jab3NCVkeHUh?=
23132-87	NXLNZZZFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{HkXGlEPTB;MD64Nlg1OyEQvF2=	MorMV2FPT0WU
EFO-21	MlXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HIdGlEPTB;MD64OFA5QSEQvF2=	MmT4V2FPT0WU
DOK	Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mk[2TWM2OD1yLki0PEDPxE1?	MV;TRW5ITVJ?
NCI-H2171	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYP3fFRpUUN3ME2wMlg1QTZizszN	M4PGdnNCVkeHUh?=
NCI-SNU-5	M1\6NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NW\KO\|lLUUN3ME2wMlg2PTdizszN	NYe4V2d6W0GQR1XS
SK-N-DZ	NYLGSJRjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYfJR\|UxRTBwOEW5OFMh\|ryP	NGjH[mVUSU6JRWK=
SNU-C2B	NE\Cd2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVnIXHlnUUN3ME2wMlg3QDBzIN88US=>	M1zacHNCVkeHUh?=
CP66-MEL	NYTLXZl1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MlXZTWM2OD1yLki3NVEh\|ryP	M2Cz[3NCVkeHUh?=
SN12C	NGHJSJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnvETWM2OD1yLki4OlM4KM7:TR?=	MWDTRW5ITVJ?
A172	M3;6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTBwOEi2PVgh\|ryP	MWrTRW5ITVJ?
NCI-H2347	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17UcGlEPTB;MD64PFc2OyEQvF2=	MmjoV2FPT0WU
NCI-H2228	NW\pbVZwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVLpWGI6UUN3ME2wMlg6OzN7IN88US=>	NFXuVpVUSU6JRWK=
SNU-387	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{XwV2lEPTB;MD65NFI3PCEQvF2=	NGPrTXlUSU6JRWK=
SK-MEL-24	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MoXiTWM2OD1yLkmxN\|Q1KM7:TR?=	MYrTRW5ITVJ?
MDA-MB-468	NWOzWVJNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1;6NmlEPTB;MD65NVc{KM7:TR?=	NXvBNWN6W0GQR1XS
NCI-H1694	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{f4[WlEPTB;MD65NVg4PiEQvF2=	M3fDbHNCVkeHUh?=
CCF-STTG1	M2X3dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NV;rcYJ2UUN3ME2wMlkzPjN5IN88US=>	M{DvN3NCVkeHUh?=
K052	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlryTWM2OD1yLkm0NFQ4KM7:TR?=	NGDDTWFUSU6JRWK=
NCI-H446	MkLwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVLJR\|UxRTBwOUWwNUDPxE1?	NFz4RolUSU6JRWK=
MFE-280	MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M4XDRWlEPTB;MD65OlI6OSEQvF2=	NHnEfmpUSU6JRWK=
KU812	NWDuSpFDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M2LSUWlEPTB;MD65PVM5QSEQvF2=	M4fHbnNCVkeHUh?=
MDA-MB-361	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1jUemlEPTB;MD65PVc4PyEQvF2=	Ml7nV2FPT0WU
Raji	M1\SNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUXJR\|UxRTFwMEKyOlch\|ryP	NXvteYY3W0GQR1XS
TE-6	NV7xemRET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MUjJR\|UxRTFwMEO1OlYh\|ryP	MULTRW5ITVJ?
CAL-148	M{PZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MV;JR\|UxRTFwMES0OFMh\|ryP	MU\TRW5ITVJ?
NCI-H1963	NXzZdZJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX\JR\|UxRTFwMES1OVMh\|ryP	MULTRW5ITVJ?
SK-N-AS	M4PxVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVvaeIVIUUN3ME2xMlA1Pjh3IN88US=>	MnrBV2FPT0WU
RERF-LC-MS	MoDmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MlTvTWM2OD1zLkC2N\|Q6KM7:TR?=	MlnrV2FPT0WU
BEN	NWnSXm41T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXjJR\|UxRTFwMEexN\|ch\|ryP	NH\LSolUSU6JRWK=
CAS-1	NELLeIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFfofo5KSzVyPUGuNFkyOjNizszN	NVzU[pd4W0GQR1XS
SW780	MnP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGDkcnZKSzVyPUGuNFkyQDFizszN	MU\TRW5ITVJ?
LU-65	NVGzUY5OT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYTJR\|UxRTFwMEm0NUDPxE1?	MnTHV2FPT0WU
D-283MED	M13mUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVfaSYJsUUN3ME2xMlEzOjd{IN88US=>	Mmi1V2FPT0WU
HCC2157	MmryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HJS2lEPTB;MT6xN\|Y1OiEQvF2=	MlTPV2FPT0WU
RCC10RGB	NYTNR3hqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NU\KfWRNUUN3ME2xMlE1ODB4IN88US=>	MWPTRW5ITVJ?
PLC-PRF-5	NFrSNWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MonCTWM2OD1zLkG1NlI6KM7:TR?=	M1rMfnNCVkeHUh?=
H4	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4X2cGlEPTB;MT6xOVQ{QSEQvF2=	M13He3NCVkeHUh?=
TUR	NGH3SGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MlHlTWM2OD1zLkG1O\|UzKM7:TR?=	MVHTRW5ITVJ?
NCI-H2141	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NE[3eXdKSzVyPUGuNVg6PDZizszN	MXLTRW5ITVJ?
PFSK-1	NIjVfm9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NW[0ZnpYUUN3ME2xMlIxPTN{IN88US=>	Mn3BV2FPT0WU
SK-MEL-28	Mkj3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NULhO29zUUN3ME2xMlI{OjJzIN88US=>	NEPtSlZUSU6JRWK=
SCC-9	NGTQfJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MkfwTWM2OD1zLkKzOlY2KM7:TR?=	MWrTRW5ITVJ?
T47D	M3yw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYfJR\|UxRTFwMkO2PVYh\|ryP	NGHPUnFUSU6JRWK=
TCCSUP	NEPEVmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmDOTWM2OD1zLkK1NFI6KM7:TR?=	NV7WW3R{W0GQR1XS
SU-DHL-1	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVXJR\|UxRTFwMkWxNVgh\|ryP	NGLzcXhUSU6JRWK=
HL-60	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NXrzcHBQUUN3ME2xMlI2PTh6IN88US=>	NX;QTY9kW0GQR1XS
NCI-H1436	MoXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1HNPGlEPTB;MT6yOlE1QSEQvF2=	NYnhR\|FxW0GQR1XS
DMS-114	NIHlTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUXJR\|UxRTFwMk[2N\|Ih\|ryP	M2\hXnNCVkeHUh?=
BOKU	MnPNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXfJR\|UxRTFwMkiwPVUh\|ryP	MmWxV2FPT0WU
MS-1	NEKyfmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1vMdWlEPTB;MT6yPVA3QSEQvF2=	NG[0R2tUSU6JRWK=
NCI-H661	Ml\tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2HZW2lEPTB;MT6zNFQ4QCEQvF2=	MlLyV2FPT0WU
HT-3	NUXwendKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	Mon0TWM2OD1zLkOwOVI6KM7:TR?=	MoPpV2FPT0WU
CAL-54	MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYPJR\|UxRTFwM{C3NlUh\|ryP	NEOzVXNUSU6JRWK=
SW1463	NH7je\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MojRTWM2OD1zLkOxPFczKM7:TR?=	MonNV2FPT0WU
COLO-668	M{LMV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NIOxS29KSzVyPUGuN\|MxPTZizszN	MX3TRW5ITVJ?
PANC-08-13	NGHF[JhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXvJR\|UxRTFwM{O4NFMh\|ryP	MUjTRW5ITVJ?
BB49-HNC	NXK2VFliT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkXKTWM2OD1zLkO0NFEh\|ryP	MYfTRW5ITVJ?
M059J	NHT4ToNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFnWfHlKSzVyPUGuN\|U5OzJizszN	NGDrcFBUSU6JRWK=
NCCIT	M4H4dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEfGfW9KSzVyPUGuN\|c6QDhizszN	NEnxOYRUSU6JRWK=
LN-405	M4rBc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYPJR\|UxRTFwM{myOlQh\|ryP	MnnjV2FPT0WU
UMC-11	NXvISnFVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NH;FOnlKSzVyPUGuN\|k6QTZizszN	MWPTRW5ITVJ?
NB5	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1KyO2lEPTB;MT60NVIzPyEQvF2=	MlT6V2FPT0WU
TE-441-T	M2i0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnu4TWM2OD1zLkSyPFE4KM7:TR?=	M{TpcnNCVkeHUh?=
ME-180	M{Hhcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MkOxTWM2OD1zLkS0N\|kzKM7:TR?=	MWjTRW5ITVJ?
HCC70	M4nzNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlnLTWM2OD1zLkS2NFk3KM7:TR?=	NGKwZ3lUSU6JRWK=
no-10	MmDhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2j1S2lEPTB;MT60OlE5OSEQvF2=	M4q0SHNCVkeHUh?=
JEG-3	MmPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHi0N\|ZKSzVyPUGuOVAyOzJizszN	NXvScoRNW0GQR1XS
no-11	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYLJR\|UxRTFwNUC4PFIh\|ryP	NGrwcJVUSU6JRWK=
CHP-126	M4rPWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NHPr[\|hKSzVyPUGuOVY3QTFizszN	M{\md3NCVkeHUh?=
EGI-1	NEjDR5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MY\JR\|UxRTFwNUiwNlUh\|ryP	MnXhV2FPT0WU
D-392MG	MlHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DSbmlEPTB;MT61PVY{KM7:TR?=	MlvNV2FPT0WU
RT4	NIrvPWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFTNOmtKSzVyPUGuOVk3OzdizszN	MkHBV2FPT0WU
A204	MlraS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUTJR\|UxRTFwNUm4NFEh\|ryP	MVfTRW5ITVJ?
NCI-H1304	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NEn3V3lKSzVyPUGuOlM2QTFizszN	Ml[5V2FPT0WU
Becker	MlizS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXzoXY9[UUN3ME2xMlY1OjRzIN88US=>	M1;zeXNCVkeHUh?=
OE19	NGnEZlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWnWSZdFUUN3ME2xMlY2PTF6IN88US=>	M1vNSHNCVkeHUh?=
EKVX	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHzsNmpKSzVyPUGuOlU3OThizszN	MXnTRW5ITVJ?
KLE	NHKyW\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXyzcHU2UUN3ME2xMlY2PzF2IN88US=>	MXPTRW5ITVJ?
K-562	M4jZbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELiflVKSzVyPUGuOlcxOzdizszN	M2WxOHNCVkeHUh?=
MDA-MB-175-VII	M1XEXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MmfoTWM2OD1zLk[4PVk4KM7:TR?=	MluwV2FPT0WU
NCI-H716	NFvlVo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYLJR\|UxRTFwNkmzNFQh\|ryP	M3jMWXNCVkeHUh?=
Caov-3	NInkelBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2\HSGlEPTB;MT62PVQyOyEQvF2=	NInTNmNUSU6JRWK=
HCC1187	MlPiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYrLbmRtUUN3ME2xMlcxPTR3IN88US=>	NUS5UWtZW0GQR1XS
CAKI-1	MoTQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTFwN{KyPVIh\|ryP	Ml7FV2FPT0WU
MOLT-16	MlmzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2rUXmlEPTB;MT63N\|MxPyEQvF2=	NEj0ZYRUSU6JRWK=
PC-3	M1uxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MXHJR\|UxRTFwN{WwPEDPxE1?	Mk\lV2FPT0WU
DV-90	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGD2NFdKSzVyPUGuO\|U2QDVizszN	NU\Gc4xoW0GQR1XS
RXF393	M2nRdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYnJR\|UxRTFwN{eyPVQh\|ryP	MkXUV2FPT0WU
SK-NEP-1	M1fVV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVSxO2d3UUN3ME2xMlgzOzN7IN88US=>	MUHTRW5ITVJ?
HCC1419	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MYjJR\|UxRTFwOEK2PVIh\|ryP	NFXMcZRUSU6JRWK=
BV-173	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M17kVmlEPTB;MT64Nlk6PSEQvF2=	M3PIeXNCVkeHUh?=
MKN7	NEixW4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXr4NZVHUUN3ME2xMlg6OjJizszN	MU\TRW5ITVJ?
LAN-6	MlO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjKTZR1UUN3ME2xMlg6PTV\|IN88US=>	MnztV2FPT0WU
Mo-T	MlzOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYTHWmFlUUN3ME2xMlkxODN7IN88US=>	NYfORXBOW0GQR1XS
HCC1395	NIPRN4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NVzTRo5EUUN3ME2xMlkzQDZ\|IN88US=>	MmLhV2FPT0WU
HC-1	M1y3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4O3NGlEPTB;MT65N\|Q4KM7:TR?=	MlvpV2FPT0WU
HPAF-II	NH3xbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M2HVbGlEPTB;MT65OFQyQCEQvF2=	NYPzfGFNW0GQR1XS
CPC-N	NHfJc4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX[1eVdsUUN3ME2xMlk5ODB{IN88US=>	MWTTRW5ITVJ?
MKN45	NITadlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NWe4WJRYUUN3ME2xMlk6OTF7IN88US=>	MnzzV2FPT0WU
NCI-H1693	NFvkXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4roPGlEPTB;Mj6wNFQ{OyEQvF2=	MmrlV2FPT0WU
SHP-77	NH7Xb\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3HMb2lEPTB;Mj6wNFU{OyEQvF2=	NW\mc3B7W0GQR1XS
NCI-H1522	MnTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MoC2TWM2OD1{LkCxO\|I1KM7:TR?=	M{\TOHNCVkeHUh?=
SW1573	NGXCfWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXnDR3d6UUN3ME2yMlAzOiEQvF2=	MVzTRW5ITVJ?
DBTRG-05MG	Mk\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mnr1TWM2OD1{LkC2NFg4KM7:TR?=	NX3NSopEW0GQR1XS
SCC-4	NX3WN2lQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVj1[2ZuUUN3ME2yMlE1OzFizszN	M2nnfHNCVkeHUh?=
DMS-153	NXzIXmNiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NUHYZ2lsUUN3ME2yMlE3PjZ6IN88US=>	MVHTRW5ITVJ?
MDA-MB-415	Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3TnOGlEPTB;Mj6xO\|UzKM7:TR?=	NFPsRphUSU6JRWK=
NCI-H2126	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M4PkbWlEPTB;Mj6yNlg5QCEQvF2=	MUPTRW5ITVJ?
MDA-MB-453	NHTGdIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF\Ecm5KSzVyPUKuNlM{OiEQvF2=	MWLTRW5ITVJ?
U-87-MG	NUPHPJZQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NW\2UnR2UUN3ME2yMlI5PTl{IN88US=>	NXL6ZoNUW0GQR1XS
LNCaP-Clone-FGC	M{\GZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF7jVXhKSzVyPUKuN\|AyODJizszN	NHXzUVBUSU6JRWK=
NCI-H1581	NES3ZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTSTYF3UUN3ME2yMlMzOTB3IN88US=>	NED4dWJUSU6JRWK=
BC-3	M3TVXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4XxWGlEPTB;Mj6zOlUxQSEQvF2=	MlTxV2FPT0WU
HCC38	NWjkSZY4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVXJR\|UxRTJwM{i0OFch\|ryP	NEnnOYdUSU6JRWK=
HCC2218	MnLGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYLJR\|UxRTJwNEC4NFkh\|ryP	NWnlXJA4W0GQR1XS
RO82-W-1	M{i3U2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUPJR\|UxRTJwNEGyOUDPxE1?	MoixV2FPT0WU
C2BBe1	Ml;oS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NV3yPWxTUUN3ME2yMlQyPTd6IN88US=>	MU\TRW5ITVJ?
LAMA-84	M1;RUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUGzZmNLUUN3ME2yMlU4OzZ6IN88US=>	MoDRV2FPT0WU
GMS-10	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUPhT4Z1UUN3ME2yMlU4PjFzIN88US=>	NE\HVoFUSU6JRWK=
GCT	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mk\0TWM2OD1{LkW4Olk1KM7:TR?=	M3:1TnNCVkeHUh?=
SK-CO-1	M3LsXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NY\sOGF6UUN3ME2yMlYyPjZizszN	NU\CTWdIW0GQR1XS
NCI-H526	M2[0S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NFrBNJFKSzVyPUKuOlM1PSEQvF2=	NFvRWmZUSU6JRWK=
SW1088	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{jXdGlEPTB;Mj63O\|g{QSEQvF2=	NYjXV2w1W0GQR1XS
HT55	M3vSSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXe1TWN[UUN3ME2yMlc5Pjl3IN88US=>	M375OnNCVkeHUh?=
NB10	NGnkdopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXTrWYRPUUN3ME2yMlgyPzR6IN88US=>	M{izS3NCVkeHUh?=
UACC-893	MlrES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;nNoNjUUN3ME2yMlg2PzR7IN88US=>	M4PtT3NCVkeHUh?=
NCI-H1618	NHfIRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MoPOTWM2OD1{Lki4NVU{KM7:TR?=	M{XKcnNCVkeHUh?=
NCI-H1092	M4q5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEjTcFRKSzVyPUOuNFc5OTJizszN	MljKV2FPT0WU
SBC-1	NVzr[pRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MVvJR\|UxRTNwMEi1OVMh\|ryP	MX;TRW5ITVJ?
NCI-H1623	NXzxTGhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{DGR2lEPTB;Mz6wPVM1KM7:TR?=	Ml\JV2FPT0WU
SiHa	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDSfW5VUUN3ME2zMlEyQTd5IN88US=>	M17rc3NCVkeHUh?=
D-263MG	M3ftemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWHJR\|UxRTNwMUS3PFgh\|ryP	MnnMV2FPT0WU
NCI-H1573	NHrNTnpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MV\JR\|UxRTNwMUm2OFEh\|ryP	M{DpVHNCVkeHUh?=
NCI-H82	M3zYVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4rqbmlEPTB;Mz6zOFQ{QSEQvF2=	MnLjV2FPT0WU
NCI-H2196	NHvFd5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MX;JR\|UxRTNwM{WwNFgh\|ryP	M{X4dHNCVkeHUh?=
MFM-223	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXTJR\|UxRTNwM{ezOVEh\|ryP	MXnTRW5ITVJ?
COLO-678	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M36wbmlEPTB;Mz6zPFE5PiEQvF2=	NIHBRm9USU6JRWK=
EW-3	NY\tcolzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEe0bXFKSzVyPUOuOFA6PSEQvF2=	M1nCVHNCVkeHUh?=
MHH-NB-11	M2Lad2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoH6TWM2OD1\|LkS0NFY6KM7:TR?=	M1T4NHNCVkeHUh?=
EM-2	MoTUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVq2O\|NKUUN3ME2zMlY{QThizszN	MWTTRW5ITVJ?
FTC-133	MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{TCOGlEPTB;Mz62OVQ2QCEQvF2=	MmfhV2FPT0WU
NCI-H209	MkXiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYLpUVJDUUN3ME2zMlY4PjV\|IN88US=>	NY\JcJRiW0GQR1XS
TGBC24TKB	Mnf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHGRWJKSzVyPUOuOlg{PTVizszN	NX7pb\|RMW0GQR1XS
LC-1F	NIPhfG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4XncWlEPTB;Mz63NVc3PCEQvF2=	NU\KXmhlW0GQR1XS
C-4-II	Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUT0XIdXUUN3ME2zMlc2PjR\|IN88US=>	M3vkN3NCVkeHUh?=
NCI-H1650	NF34c5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M3PsfWlEPTB;Mz63PFQ2PSEQvF2=	MWjTRW5ITVJ?
JVM-2	M2nZ[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NF;YRo9KSzVyPUOuPVM3OzlizszN	MnnQV2FPT0WU
CaR-1	M2[yU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3G1[mlEPTB;Mz65O\|YyPyEQvF2=	NFPLN4VUSU6JRWK=
MDA-MB-134-VI	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mlf6TWM2OD12LkCyPVUzKM7:TR?=	NGTtVVhUSU6JRWK=
NCI-H719	M2DwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn3uTWM2OD12LkG1N\|g5KM7:TR?=	NH21[WdUSU6JRWK=
GOTO	MmjuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MWnJR\|UxRTRwMkm3NFUh\|ryP	M2XNZnNCVkeHUh?=
NCI-N87	NUPxTVd[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PIVmlEPTB;ND6zPFgzOSEQvF2=	NWG3d4NIW0GQR1XS
NB6	MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M2\oTWlEPTB;ND60NlUxQSEQvF2=	MYXTRW5ITVJ?
DSH1	M1X3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3:4cmlEPTB;ND60O\|EyPiEQvF2=	MmXmV2FPT0WU
BT-20	M4HxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MVXJR\|UxRTRwNEmwNFIh\|ryP	NULafZM6W0GQR1XS
NCI-H1882	M4TUUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MknxTWM2OD12LkWwOVch\|ryP	NXnZV4JSW0GQR1XS
WM-115	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVHJR\|UxRTRwNUC4PFEh\|ryP	M3zOTHNCVkeHUh?=
SKG-IIIa	NIL4dFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnKwTWM2OD12Lk[3O\|ch\|ryP	NYP4eW91W0GQR1XS
NCI-H69	NVjhPHdiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NFnKWGhKSzVyPUSuO\|AzPzVizszN	MV7TRW5ITVJ?
MSTO-211H	MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHyye3RKSzVyPUSuPFM2PjVizszN	NIPKbotUSU6JRWK=
Mewo	Mn\FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVHJR\|UxRTRwOU[zNVMh\|ryP	NGr0N2ZUSU6JRWK=
GI-ME-N	NF;uco1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	Mn60TWM2OD13LkCwOVA6KM7:TR?=	Ml25V2FPT0WU
T98G	MoHFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHPLbJdKSzVyPUWuNFY2ODhizszN	MnvJV2FPT0WU
ECC4	M{HDOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlrjTWM2OD13LkC5N\|czKM7:TR?=	NICwN2tUSU6JRWK=
EW-11	NHjYZXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NH3EeIhKSzVyPUWuNVgxQTlizszN	MXXTRW5ITVJ?
COLO-800	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1TIOGlEPTB;NT6xPVM1QSEQvF2=	NUDk[o9HW0GQR1XS
NCI-H1755	M3vtZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWjJR\|UxRTVwMkOwNlch\|ryP	NGC2TVhUSU6JRWK=
KMS-12-PE	NVH3[IpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWS5Z\|B3UUN3ME21MlM2ODh3IN88US=>	NFzQb4JUSU6JRWK=
HCC1954	NH7DR2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYnJR\|UxRTVwOEW5O\|Eh\|ryP	MUPTRW5ITVJ?
NCI-H187	NH;HXXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1TGU2lEPTB;NT65Nlk5QSEQvF2=	NUPlUFl2W0GQR1XS
LU-165	M{TCeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnLN4k5UUN3ME21Mlk6ODB{IN88US=>	NEXDSXlUSU6JRWK=
YAPC	M{jPSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWDJR\|UxRTVwOUmwOlgh\|ryP	MoLwV2FPT0WU
LU-139	M3jkWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYTiW3lbUUN3ME22MlA5OzZ6IN88US=>	MWTTRW5ITVJ?
D-502MG	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3TSZ2lEPTB;Nj6zNlA1PyEQvF2=	NUDG[3NjW0GQR1XS
IST-SL1	NYjH[GpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVj5UYFpUUN3ME22MlU{QTR6IN88US=>	MmHOV2FPT0WU
DG-75	M37zb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYjJR\|UxRTZwOEi3PFYh\|ryP	NEXPU4hUSU6JRWK=
NCI-H1155	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX\JR\|UxRTZwOUW1PFEh\|ryP	Ml;2V2FPT0WU
EFE-184	MmHOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	Mn3XTWM2OD15LkOxOlk2KM7:TR?=	NGPHfFJUSU6JRWK=
AsPC-1	NH30N3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEXhWGJKSzVyPUeuOFg5ODdizszN	NYH4dmN5W0GQR1XS
SW948	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NHjxXFVKSzVyPUeuOVg{QTVizszN	NIjScmZUSU6JRWK=
NCI-H524	Mk\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFXX[YZKSzVyPUmuOVg3OjhizszN	MnTZV2FPT0WU
KOSC-2	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	Mn3XTWM2OD17Lk[yPFM1KM7:TR?=	NX;NZoZiW0GQR1XS
T-24	M4L4c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NE\Ud\|dKSzVyPUmuPVQ1OTVizszN	NULvdYI6W0GQR1XS
NCI-H748	MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NFPBc2FKSzVyPUGwMlY{QTdizszN	Mo\XV2FPT0WU
NCI-H23	NHjvPJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M1nGVWlEPTB;MUCuOlQ1OiEQvF2=	MVLTRW5ITVJ?
UACC-812	NFuxdmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUi4eowyUUN3ME2xNU44OTdizszN	MlnoV2FPT0WU
SCLC-21H	NWHnWZJuT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M{XpSGlEPTB;MUKuNVU2OSEQvF2=	Mm\FV2FPT0WU
NCI-SNU-16	NEPrflJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHLWb3BKSzVyPUGzMlEzPThizszN	NHKwfHJUSU6JRWK=
HD-MY-Z	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUTJR\|UxRTF2Lk[zOlMh\|ryP	M2LRfHNCVkeHUh?=
SK-N-FI	NXzPdYNwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NWq3UZpXUUN3ME2xOE45QTF{IN88US=>	NVm4[Gs3W0GQR1XS
LB647-SCLC	NWO3XVVNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MorVTWM2OD1zNT63NVk2KM7:TR?=	NX74cmZTW0GQR1XS
NCI-H345	MmHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NEjmO5ZKSzVyPUG3MlM1OyEQvF2=	NYPlS3NOW0GQR1XS
NCI-H1563	MknaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MYfJR\|UxRTF6Lke2NFEh\|ryP	MUXTRW5ITVJ?
RL	MoGwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MVnJR\|UxRTJzLkK2OVYh\|ryP	M2TEcnNCVkeHUh?=
KY821	NFzC[IVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYrJR\|UxRTJ{LkC1OVMh\|ryP	NIDXZm5USU6JRWK=
JVM-3	NEG3XVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXvtWXdrUUN3ME2yOU4xPDF\|IN88US=>	MUDTRW5ITVJ?
NCI-H1793	NGXrfm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MYHJR\|UxRTJ6LkW0PVkh\|ryP	NX7VN3BYW0GQR1XS
LU-134-A	NGqzb2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF7zSY9KSzVyPUOwMlIxOzdizszN	NYGwbXE4W0GQR1XS
NCI-H1395	Mo\mS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MnH1TWM2OD1\|Mj6yOFMyKM7:TR?=	MWjTRW5ITVJ?
NCI-H1993	MnvXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXjJR\|UxRTN{LkiyNVgh\|ryP	Ml2xV2FPT0WU
P31-FUJ	MofKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWXpZpdDUUN3ME2zN{41QDl7IN88US=>	MnLlV2FPT0WU
LS-513	MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M3HLWGlEPTB;M{WuPFg4QSEQvF2=	M176Z3NCVkeHUh?=
SK-MEL-1	M1PMWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NUPNToh[UUN3ME20NE4{PDl7IN88US=>	M{HMNnNCVkeHUh?=
SW684	M2SwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M2TJWGlEPTB;NEOuPVY3OSEQvF2=	M1rFeXNCVkeHUh?=
COR-L88	NGjWXmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M330e2lEPTB;NESuNFY3PSEQvF2=	M1PnWXNCVkeHUh?=
NCI-H889	NYnMZnZHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXHJR\|UxRTR3LkCwPFch\|ryP	M3WzSnNCVkeHUh?=
TALL-1	NGXicpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGrQPJJKSzVyPUS2MlEyQTlizszN	NG\4clJUSU6JRWK=
KARPAS-299	M1LzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\NTWM2OD12Nz6xPVk{KM7:TR?=	NHvwNHlUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Cyclin D1 / p27 Kip1 ; PubMed: 28382170 Theranostics Western blotting showed that Obatoclax impacted cell cycle distribution through lowering cyclin D1 in K1 cells but in BCPAP cells, it impacted expression of p27 Kip1 rather than cyclin D1. p-Cyclin D1 ; PubMed: 28035994 Int J Mol Sci Cell line-dependent effect of obatoclax on cyclin D1 T286 phosphorylation. HCT116, HT-29, and LoVo cells were subject to 24 h-treatment with obatoclax (200 nM), followed by immunoblotting to evaluate the levels of threonine 286 (T286)-phosphorylated cyclin D1 (p-Cyclin D1) at indicated time points. α-Tubulin levels served as equal loading control; p-GSK3β / GSK3β / p-ERK / ERK / p-p38 / p38; PubMed: 28035994 Int J Mol Sci Obatoclax inhibits GSK3β but activates p38 (MAPK), while barely affecting ERK1/2 activity in HT-29 cells. HT-29 cells were exposed to 200 nM of obatoclax for 24 h. The status of activation of GSK3β, ERK1/2, and p38(MAPK) at indicated time points was determined by immunoblotting for corresponding phosphorylation. Specifically, serine 9-phosphorylation of GSK3β (p-GSK3β) reveals inhibition of GSK3β activity, whereas dual phosphorylation at threonine 202/tyrosine 204 of ERK1/2 (p-ERK1/2) and threonine 180/tyrosine 182 of p38 MAPK (p-p38) indicate activation of ERK1/2 and p38(MAPK), respectively. α-Tubulin levels served as equal loading control;	28382170 28035994
Growth inhibition assay	Cell proliferation ; PubMed: 28035994 Int J Mol Sci Obatoclax inhibits colorectal cancer cell proliferation. Human colorectal carcinoma cell lines HCT116, HT-29, and LoVo cells were treated with obatoclax (0, 50, 100, 200 nM) for 24, 48, and 72 h. The numbers of cells at each time point were counted using a Neubauer chamber. Data were presented as the percentage relative to the drug-untreated control. Cell viability; PubMed: 21368880 Cell Death Dis H727 NSCLC cells are resistant to obatoclax. H727 and H1975 NSCLC cells were treated with obatoclax at the indicated doses for 48 (left) or 72 h (right), and the viability of cells determined by ViaLight assay. The EC50 values of cells at 48 h were; H1975 267 nM; H727 3.2 μM. The EC50 values of cells at 72 h were; H1975 66 nM; H727 621 nM. Data are expressed as mean±S.D.	28035994 21368880

In vivo

Obatoclax also exhibits high antitumor activity in SCID mice bearing human C33A cerivical carcinoma tumors at a dose of 0.5 mg/kg. ^[1]

Protocol

Kinase Assay:^[1]	- Collapse Bcl-2 Binding affinity calculation: A predicted binding affinity for Obatoclax binding to BCL-2 is calculated using the SIE scoring function. ^[4] As a control in determining the reliability of the calculation, predicted binding affinities K_i) are calculated for a set of 12 small molecules with experimentally measured binding affinities to BCL-2.
Cell Research:^[2]	- Collapse Cell lines: Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) Concentrations: ~10 μM Incubation Time: 48-72 hours Method: Obatoclax is dissolved in DMSO at a stock concentration of 5 mM. Cell viability is assayed by MTT. Human MM cells (HMCLs), peripheral blood lymphocytes (PBLs), bone marrow stromal cells (BMSCs) are seeded in 96-well plates at a density of 2 × 10⁴ per well for HMCLs or 5~10 × 10³ for PBLs. Various concentrations of Obatoclax are added to the cells, with or without IGF-1 (50 ng/mL) or IL-6 (10 ng/mL). Cells are incubated for 48-72 hours and cell viability is determined. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: Female BALB/c or CB17 SCID/SCID mice bearing SW480, C33A, PC3, and 4T1 cells are used. Dosages: 0.0313, 0.25, 0.5 and 2 mg/kg Administration: Administered intravenously (tail vein) once a day (Only for Reference)

References

[4] Naim M, et al. J Chem Inf Model, 2007, 47(1), 122-133.

- Collapse

Solubility (25°C)

In vitro	DMSO	83 mg/mL (200.73 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 30% PEG400+0.5% Tween80+5% propylene glycol For best results, use promptly after mixing.	30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Obatoclax Mesylate (GX15-070) SDF

Molecular Weight	413.49
Formula	C₂₀H₁₉N₃O.CH₄O₃S
CAS No.	803712-79-0
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=CC(=C(N1)C=C2C(=CC(=C3C=C4C=CC=CC4=N3)N2)OC)C.CS(=O)(=O)O

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (Different batches have different solubility ratios, please contact Selleck to provide you with the correct ratio)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2020-01-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT00438178	Completed	Drug: Obatoclax mesylate (GX15-070MS)	Hematological Malignancies	Gemin X\|Teva Pharmaceutical Industries	October 2005	Phase 1
NCT00600964	Completed	Drug: GX15-070MS	Chronic Lymphocytic Leukemia	Gemin X\|Teva Pharmaceutical Industries	September 2004	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Pan Bcl-2 Inhibitor

ABT-737 : Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.
Most Potent Bcl-2 Inhibitor

ABT-263 (Navitoclax) : Bcl-xL, K_i≤ 0.5 nM; Bcl-2, K_i≤ 1 nM; Bcl-w, K_i≤ 1 nM.
Newest Bcl-2 Family Activator

BAM7 : Direct and selective activator of proapoptotic Bax with EC50 of 3.3 μM.
Classic Bcl-2 Inhibitor

ABT-737 : BH3-mimetic inhibitor, Bcl-xL, EC50=78.7 nM; Bcl-2, EC50=30.3 nM; Bcl-w, EC50=197.8 nM.

Related Bcl-2 Products

A-1210477 ^New

A-1210477 is a potent and selective MCL-1 inhibitor with K_i and IC50 of 0.454 nM and 26.2 nM, respectively, >100-fold selectivity over other Bcl-2 family members.
MI-773 (SAR405838) ^New

MI-773 (SAR405838) is an orally available MDM2 antagonist with K_i of 0.88 nM. Phase 1.
Navitoclax (ABT-263)

Navitoclax (ABT-263) is a potent inhibitor of Bcl-xL, Bcl-2 and Bcl-w with K_i of ≤ 0.5 nM, ≤1 nM and ≤1 nM in cell-free assays, but binds more weakly to Mcl-1 and A1. Phase 2.
Venetoclax (ABT-199)

Venetoclax (ABT-199, GDC-0199) is a Bcl-2-selective inhibitor with K_i of <0.01 nM in cell-free assays, >4800-fold more selective versus Bcl-xL and Bcl-w, and no activity to Mcl-1. Venetoclax is reported to induce cell growth suppression, apoptosis, cell cycle arrest, and autophagy in triple negative breast cancer MDA-MB-231 cells. Phase 3.

Features:Re-engineered version of ABT-263 (Navitoclax).
ABT-737

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. ABT-737 induces mitochondrial pathway apoptosis and mitophagy. Phase 2.
UMI-77

UMI-77 is a selective Mcl-1 inhibitor with Ki of 490 nM, showing selectivity over other members of Bcl-2 family.
TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.29 μM, 1.11 μM and 0.26 μM in cell-free assays, respectively.
Sabutoclax

Sabutoclax (BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
(R)-(-)-Gossypol acetic acid

(R)-(-)-Gossypol (AT-101) acetic acid, the R-(-) enantiomer of Gossypol acetic acid, binds with Bcl-2, Bcl-xL and Mcl-1 with K_i of 0.32 μM, 0.48 μM and 0.18 μM in cell-free assays; does not inhibit BIR3 domain and BID. AT-101 simultaneously triggers apoptosis and a cytoprotective type of autophagy. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Obatoclax Mesylate (GX15-070)